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We are all born with a divine fire in us. Our efforts should be to give wings to this fire 
and fill the world with the glow of its goodness. 













Mitochondria are vital cellular organelles that produce the majority of the energy 
required by cells and are therefore represented as "the power house of the cell". 
Cellular energy, in the form of adenosine triphosphate (ATP), is generated through 
oxidative phosphorylation (OXPHOS), which is energized by the redox reactions of 
the electron transport chain (ETC) in mitochondria. Mitochondria are essential for 
maintaining metabolic homeostasis, fatty-acid metabolism, nucleotide synthesis and 
cellular redox balance, in addition to producing ATP.  
Given the multitude of mitochondrial functions, failure of any of them can lead to 
mitochondrial dysfunction that can have drastic consequences. It can lead to cell loss, 
organ failure and even death. Mitochondrial disorders are commonly associated with 
debilitating childhood onset diseases with no known cure. Current therapeutic 
approaches are largey symptomatic, such as dietary modification for diabetes, anti-
convulsant drugs to control seizures, physical exercise for hypotonia, pacemaker 
implants for cardiac rhythm abnormalities and cochlear implants for sensorineural 
deafness. However, these are not a permanent solution or cure for severe disorders 
caused by genetic mutations or irreversible physical damage.  
Cardiomyopathy, failure of the heart muscle, is one of the most common symptoms 
of mitochondrial disorders, while cardiomyopathies almost always are associated with 
mitochondrial dysfunction. In severe forms of cardiomyopathy, the ultimate treatment 
option of heart transplantation is invasive and carries high risk, and the waiting list for 
a functional healthy heart is increasingly outstripping availability. 
I have investigated the use of a mitochondrial enzyme, the alternative oxidase (AOX), 
which is found in plants and lower eukaryotes, as well as in primitive metazoans but 
not in mammals as a new approach to better understand the underlying molecular 
mechanisms of diseases involving mitochondrial dysfunction. On a broader 
perspective, this would also aid in the development of a possible treatment for 
diseases associated with mitochondrial dysfunction. If catalytically engaged, AOX 
branches the mitochondrial ETC by oxidizing ubiquinol, which accumulates in the 
reduced form if the cytochrome pathway is impaired. By doing so it reduces oxygen 
directly to water, which is typically carried out by cytochrome oxidase, and thus 
maintains redox balance by recycling NADH and FADH2, two by-products of the 
Krebs cycle and upstream metabolism. 
 
 
Focusing on different types of cardiomyopathy, my strategy has been to introduce the 
AOX gene from the tunicate Ciona intestinalis, a close relative of vertebrates, into 
mouse models of disease, using genomic manipulation. I have studied and 
characterized two transgenic mouse models expressing C. intestinalis AOX. The first 
was designed to express AOX constitutively and ubiquitously. I verified this at the 
RNA and protein level revealing high-level expression in all tissues tested, including 
the heart, with the exception of the adult brain. The mice did not show any observable 
phenotype, making them nearly indistinguishable from their wild-type littermates 
under non-stressed conditions. Heart function, as measured by ejection fraction and 
left ventricular mass, treadmill performance and grip strength were all normal in one-
year-old AOX-expressing mice. Weight was indistinguishable from that of wild-type 
littermates on chow or high-fat diet; although on ketogenic diet AOX-expressing mice 
showed a slightly mitigated weight gain, at least when caged in same-sex groups.   
A second AOX transgenic line was characterized, in which AOX expression was 
designed to be activatable by Cre-loxP-mediated removal of a STOP cassette (SNAP 
coding sequence, pA signal) located downstream of a CAG promoter and upstream 
of the AOX coding sequence. After verification of the transgenic insertion by PCR and 
Southern blotting, test activation by breeding to mice ubiquitously expressing Cre 
recombinase under the control of a β-actin promoter resulted in successful activation, 
based on ubiquitous expression of AOX and concomitant loss of SNAP expression. 
This allowed me to test the tissue-specificity of AOX-mediated modification of 
pathological phenotypes in mouse models of cardiomyopathy. 
Two different mouse models of cardiomyopathy were investigated. In the first, 
inflammatory cardiomyopathy was induced by overexpressing monocyte chemo-
attractant protein 1 (MCP1) in the cardiomyocytes, which leads to loss of cardiac 
function commencing during early adulthood (12 weeks of age). Previously published 
data showed mitochondrial structural damage, decrease in ATP levels; and 
suggested induced oxidative stress as a pathological mechanism. Although the 
majority of oxidative stress in the cardiomyocytes of Mcp1 mice is induced by the 
infiltrating monocytes, via NADPH oxidase pathway, the contribution of mitochondria 
to the production of reactive oxygen species (ROS) is not well understood. I 
hypothesized that mitochondrial ROS production, especially via a defective or 
overloaded cytochrome pathway in the mitochondrial respiratory chain, might play a 
key role in the underlying molecular mechanisms. Therefore we wanted to test 
whether AOX could mitigate it, as it has been shown to alleviate oxidative stress under 
 
 
conditions where the cytochrome pathway is dysfunctional. I found that expressing 
AOX in this model preserved cardiac ejection fraction at 12 weeks of age but not at 
later time points. At the molecular level, I determined that mitochondrial complex I-
linked respiration was severely affected in Mcp1-overexpressing mice irrespective of 
AOX expression. However, AOX preserved complex II mediated respiration. In 
theory, this should maintain mitochondrial redox homeostasis and limit oxidative 
stress and damage within mitochondria, but at the expense of ATP production and 
mitochondrial-ROS signaling. Ultrastructural analysis revealed mitochondrial damage 
in the cardiac tissue of 12 week-old Mcp1-overexpressing mice, which was alleviated 
by AOX expression. Despite this, AOX had no effect on the survival of Mcp1-
overexpressing mice, whilst cardiomyocyte-specific AOX expression actually resulted 
in earlier death than Mcp1 alone. Autophagic markers were mildly elevated in all 
cases, and metabolic changes consistent with OXPHOS dysfunction were essentially 
unaffected by AOX expression in the Mcp1 mouse model. Overall, I conclude that 
AOX is insufficient to block lethal damage to mitochondria and/or other cellular 
components in this inflammatory cardiomyopathy model, despite transient beneficial 
effects. Previously, West et al (2011) and Mills et al (2016) reported on the 
significance of mitochondrial ROS in inducing macrophage activity in a LPS-induced 
inflammatory mouse model. Additionally, Mills et al (2016) also showed AOX 
expression prevented LPS-induced lethality in mice, where succinate-dependent 
ROS production in the ETC was reported to be the underlying cause for the observed 
severe phenotype. However, since AOX was unable to prevent lethality in Mcp1 mice, 
it is indicative that the ROS production in this inflammatory model might not be 
dependent on the ETC. 
The second model I studied was of Cox-deficient mitochondrial cardiomyopathy, 
induced by cardiomyocyte-specific knockout of Cox10, an essential enzyme of heme 
a biosynthesis. Cox10 knockout in the heart was lethal within the first days or weeks 
of life, and concomitant AOX expression had hardly any effect on this. Mice with 
heterozygous knockout of Cox10 survived for months but eventually succumbed to 
heart failure. However, this phenotype was produced by the cardiomyocyte-specific 
Cre expression alone, and was again exacerbated by AOX activation, despite 
transient improvements in cardiac performance in young mice. 
In conclusion, AOX can serve as a valuable tool to study disease mechanisms where 
mitochondrial dysfunction is proposed to play a key role in the pathophysiology. 
Although AOX did not rescue the disease models I studied, it did shed light on 
 
 
underlying molecular mechanisms. Considering the fact that AOX showed a partial, 
if transient, functional rescue in both of the heart failure models investigated, it might 
yet be relevant as a potential therapeutic option. Further research is necessary to 
fully understand the therapeutic potential of AOX, either by itself or in combination 
with other treatments that address different pathological processes, as well as the 






Mitokondriot ovat elintärkeitä soluorganelleja, jotka tuottavat suurimman osan solujen 
tarvitsemasta energiasta ja ovat välttämättömiä ylläpitämään useita 
aineenvaihduntareittejä. Siten mitokondrioiden toimintahäiriöt voivat usein johtaa 
solujen menetykseen, elinten vajaatoimintaan ja jopa kuolemaan. Mitokondriaaliset 
sairaudet liittyvät yleensä vakaviin lapsuuden aikaisiin sairauksiin, joille ei ole 
tunnettuja parannuskeinoja. Kardiomyopatia, sydänlihaksen vajaatoiminta, on yksi 
yleisimmistä mitokondriohäiriöiden oireista, ja se on yksi suurimmista kuolinsyistä 
maailmassa. Ymmärtääkseni paremmin sellaisten sairauksien taustalla olevia 
molekyylimekanismeja, joihin liittyy mitokondrioiden toimintahäiriöitä, etenkin 
hengityskompleksien III ja / tai IV aiheuttamia toimintahäiriöitä, olen tutkinut 
mitokondriaalista entsyymiä, vaihtoehtoista oksidaasia (AOX), joka löytyy kasveista 
ja alemmista eukaryooteista, mutta ei nisäkkäistä. Katalyyttisesti aktivoituneena AOX 
haaroittaa mitokondriaalisen hengitysketjun ohittaen hengityskompleksit III ja IV ja 
redusoiden hapen suoraan vedeksi, minkä tyypillisesti suorittaa hengityskompleksi 
IV. 
 
Keskityin tutkimaan AOX-ilmentymisen vaikutusta erityyppisissä kardiomyopatioissa. 
Tätä varten strategiani on ollut siirtää AOX-geeni Ciona intestinalis -vaippaeläimestä 
kardiomyopatiahiirimalleihin geenimanipulaatiolla. Olen tutkinut ja karakterisoinut 
kahta siirtogeenistä hiirimallia, jotka ekspressoivat C. intestinalis AOX-geeniä. 
Ensimmäinen malli oli suunniteltu ekspressoimaan AOX:ia jatkuvasti ja kaikkialla, ja 
toinen AOX-siirtogeeninen linja suunniteltiin aktivoitavaksi tietyissä kudoksissa Cre-
loxP-välitteisellä geenimanipulaatiolla. Molemmissa hiirimalleissa AOX-ekspressio 
varmistettiin RNA- ja proteiinitasoilla. Hiirillä ei ollut havaittavaa fenotyyppiä, mikä teki 
niiden erottamisen villityyppistä poikuetovereistaan lähes mahdottomaksi 
stressittömissä olosuhteissa. Ensimmäisessä mallissa normaali tai korkearasvainen 
ruokavalio ei erottanut siirtogeenisiä eläimiä villityyppisistä eläimistä, tosin 
ketogeenisellä ruokavaliolla AOX:ia ekspressoivat hiiret osoittivat hieman lievempää 
painonnousua kuin villityyppiset eläimet, ainakin ollessaan samaa sukupuolta olevien 
joukossa. 
 
Kahta erilaista kardiomyopatiahiirimallia tutkittiin. Ensimmäisessä indusoitiin 
tulehduksellinen kardiomyopatia MCP1 (monocyte chemo-attractant protein 1) 
 
 
yliekspression avulla sydänlihassoluissa, mikä johtaa sydämen toiminnan 
menettämiseen, joka alkaa varhaisessa aikuisiässä (12 viikon ikäisenä). 
Aikaisempien julkaisujen tutkimustulokset ovat osoittaneet mitokondrioiden 
rakennevaurioita, ATP-tasojen laskua, ja viittaavat indusoituun oksidatiiviseen 
stressiin patologisena mekanismina. Hypoteesin mukaan mitokondriaalisten 
reaktiivisten happiradikaalien (ROS) tuotannolla voisi olla avainrooli taustalla olevissa 
molekyylimekanismeissa. Siksi halusin testata, voisiko AOX lieventää sitä, koska sen 
on osoitettu lievittävän oksidatiivista stressiä olosuhteissa, joissa 
hengityskomplekseissa III ja / tai IV on toimintahäiriöitä. Havaitsin, että AOX:n 
ilmentäminen tässä mallissa säilytti sydämen ejektiofraktion 12 viikon iässä, mutta ei 
myöhemmin. Molekyylitasolla määrittelin, että mitokondriaalisen kompleksin I-
linkittynyt hengitys vaikutti voimakkaasti MCP1:tä yliekspressoivissa hiirissä 
riippumatta AOX-ekspressiosta. AOX kuitenkin säilytti kompleksin II välittämän 
hengityksen. Teoriassa tämän pitäisi ylläpitää mitokondrioiden redox-homeostaasia 
ja rajoittaa oksidatiivista stressiä ja vaurioita mitokondrioissa, mutta ATP-tuotannon 
ja mitokondrion ROS-signaloinnin kustannuksella. Tästä huolimatta AOX:lla ei ollut 
vaikutusta MCP1:tä yliekspressoivien hiirten selviytymiseen, kun taas sydänsolujen 
spesifinen AOX-ekspressio johti tosiasiallisesti aikaisempaan kuolemaan kuin pelkkä 
MCP1. Kaiken kaikkiaan päättelen, että AOX ei riitä estämään mitokondrioiden ja/tai 
muiden solukomponenttien tappavia vaurioita tässä tulehduksellisessa 
kardiomyopatian mallissa, huolimatta ohimenevistä hyödyllisistä vaikutuksista. Nämä 
havainnot osoittavat, että ROS-tuotanto tässä tulehduksellisessa mallissa ei ehkä ole 
riippuvainen ETC:stä. 
 
Toinen tutkimani malli oli Cox-vajaatoimintainen mitokondriaalinen kardiomyopatia, 
jonka aiheuttaa kardiomyosyyttispesifinen Cox10:n puute, hemibiosynteesin 
välttämätön entsyymi. Cox10:n geenin poisto sydämestä oli tappavaa elämän 
ensimmäisinä päivinä tai viikkoina, ja samanaikaisella AOX-ekspressiolla ei ollut juuri 
mitään vaikutusta tähän. Hiiret, joilla oli heterotsygoottinen Cox10-geenin poisto, 
selvisivät kuukausia, mutta lopulta menehtyivät sydämen vajaatoimintaan. Tämä 
fenotyyppi tuotettiin kuitenkin pelkästään kardiomyosyyttispesifisellä Cre-
ilmentymällä, ja AOX-aktivaatio pahensi sitä uudelleen, huolimatta sydämen 




Yhteenvetona voidaan todeta, että AOX voi toimia arvokkaana välineenä tutkittaessa 
sairauden mekanismeja, joissa mitokondrioiden toimintahäiriöiden uskotaan olevan 
avainasemassa patofysiologiassa. Vaikka AOX ei toiminut pelastuskeinona 
tutkimissani sairausmalleissa, se valotti taustalla olevia molekyylimekanismeja. Kun 
otetaan huomioon, että AOX osoitti olevansa osittainen, joskin ohimenevä, 
toiminnallinen pelastuskeino molemmissa tutkituissa sydämen 
vajaatoimintamalleissa, se saattaa vielä tulevaisuudessa olla potentiaalinen 
terapeuttinen vaihtoehto. Jatkotutkimukset ovat välttämättömiä, jotta voidaan täysin 
ymmärtää AOX:n terapeuttinen potentiaali, joko itsenäisesti tai yhdessä muiden 
patologisiin prosesseihin kohdistuvien hoitomenetelmien kanssa, mutta yhtä lailla 
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The mammalian heart is composed of several different cell types of which 
cardiomyocytes comprise about 30 - 50% in number (Banerjee et al., 2007, Pinto et 
al., 2016), and about 70 – 85% by volume (cited in Zhou et al., 2016), while the rest 
is composed of endothelial cells, fibroblasts, macrophages and perivascular cells 
(Pinto et al., 2016, reviewed by Gray et al., 2018). A properly functioning healthy heart 
muscle is dependent on effective communication within and function of the complex 
cellular network in the muscle. Thus, malfunction of even one cell type, whether a 
myocyte or a non-myocyte, could compromise the function of the whole organ, 
resulting in heart failure (Aoki et al., 2011, Acharya et al., 2012; reviewed by Tian et 
al., 2013, Moore-Morris et al., 2015, Gray et al., 2018, Segers et al., 2018). 
According to the WHO, cardiovascular diseases are the major cause of death, 
accounting for over 17 million every year globally, of which 85% were due to heart 
failure or stroke. Heart failure is clinically characterized as the reduced ability of the 
heart muscle to effectively pump blood. The New York Heart Association (NYHA) has 
classified 4 different stages of heart failure based on the severity of their impact on 
physical activity (Inamdar, et al., 2016). There are several possible causes of heart 
failure, including behavioral and genetic (Inamdar, et al., 2016). Irrespective of the 
nature of cause, it brings a huge personal and socio-economic burden, considering 
the fact that over three quarters of the reported heart failure cases are from low- and 
middle-income countries (source: WHO, 2017).  
Primary treatment options for early-stage heart failure symptoms address the issue 
by controlling behavioral factors like use of alcohol and tobacco, unhealthy diet and 
physical inactivity. Secondary treatment options for patients with established heart 
failure include administration of medications like beta-blockers and statins, along with 
changes in diet and improved physical activity. For patients in critical stages, the only 
option is an invasive surgery that sometimes requires a heart transplantation. 
According to WHO, thus far the availability of a healthy heart never satisfied the 
demand, making heart failure a complex and serious issue world-wide . 
To address this issue from the molecular perspective, I have used tools to study and 
better understand the biology of cardiomyocytes in conditions of mitochondrial 
respiratory dysfunction. Cardiomyocytes make up for the majority of the volume in the 
heart muscle. Effective function of the cardiomyocytes demands a high and constant 
supply of cellular energy, adenosine triphosphate (ATP), the majority of which is 
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supplied by mitochondria. Thus cardiomyocytes are among the few cell types known 
to contain a large mitochondrial mass. When and if mitochondria fail to produce 
enough ATP or maintain the metabolic homeostasis of the cell, the normal cellular 
functioning is severely affected even leading to cardiomyocyte death (Nakayama et 
al., 2007). On a larger scale, loss of cardiomyocytes results in several severe forms 
of cardiomyopathy, such as hypertrophic cardiomyopathy (Kavantzas et al., 2000), 
idiopathic dilated cardiomyopathy (Narula et al., 1999, Kavantzas et al., 2000) and 
arrhythmogenic right ventricular cardiomyopathy (Valente et al., 1998, Kavantzas et 
al., 2000). This ultimately leads to critical stages of heart failure (Nakayama et al., 
2007; reviewed by Ingwall et al., 2004, Neubauer, 2007, Chiong et al., 2011, Chen et 
al., 2010). 
Although mitochondrial dysfunction can occur due to several different reasons, I have 
addressed whether disturbed mitochondrial respiration, can potentially be the primary 
cause of mitochondrial dysfunction and the pathophysiology in the two heart failure 
models I have studied. The mitochondrial respiratory chain is the central component 
needed for OXPHOS, i.e. the process by which mitochondria generate ATP while 
reducing the inhaled oxygen to water. It is a complex process by itself involving 
several protein complexes and by-products of a larger metabolic cycle that serve as 
substrates. When the respiratory chain is defective, ATP generation is affected, 
oxygen is converted in to a highly reactive molecular species (ROS) and connected 
metabolic pathways are stalled due to the lack of reoxidation of NADH and FADH2. 
This eventually leads to a cascade of events that could potentially result in cell death 
(reviewed by Adams et al., 1996, Martin, 2010). 
To address mitochondrial dysfunction due to ETC defects, especially in the 
cytochrome pathway, I have used AOX, a naturally occurring enzyme that can branch 
the electron flow to the cytochrome pathway and reduce oxygen to water directly but 
at the cost of ATP production. This should decrease excessive ROS production and 
maintain the interlinked metabolic pathways (reviewed by Valerberghe, 2013).  
Since AOX is not naurally expressed in mammals (McDonald et al., 2004), I first 
characterized a mouse model where AOX is expressed constitutively, as a result of 
genetic manipulation. I used basic and advanced scientific methods to profile 
behavior, heart function and physical performance of the mice including an extensive 
characterization at the molecular level by studying the mitochondrial respiration, 
protein expression and overall metabolism of different tissues. I have also 
characterized a second mouse model where expression of AOX can be targeted to a 
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specific cell type using Cre-loxP recombination. After validating AOX expression in 
both of these mouse models, I have combined them with two established models of 
heart failure. In the first model, heart failure is induced by excessive inflammation 
which is proposed to be triggered by excessive ROS production and in the second 
model, heart failure is induced by disrupting the cytochrome pathway, especially 
complex IV, of mitochondrial OXPHOS.  
In the following chapter I discuss the scientific background to my thesis work by 
referring to the findings from decades of research in this field  
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2. Literature Review 
 
2.1. Mitochondria 
Mitochondria are widely recognized as the ‘power plant’ of the cell as they are the 
major source of adenosine triphosphate (ATP), the energy molecule that drives 
fundamental cellular functions. Richard Altmann (1890) reported the ubiquitous 
occurrence of these organelles and termed them ‘bioblasts’. A few years later, Carl 
Benda (1898) coined the term ‘mitochondrion’ based on the Greek words ‘mitos’ 
(thread) and ‘chondros’ (granule), from his observations of these structures during 
spermatogenesis (also see review by Ernster et al., 1981). In addition to ATP 
production, mitochondria play key roles in modulating Ca2+ homeostasis (reviewed by 
Vandecasteele et al., 2001; Clapham, 2007; Giorgi et al., 2012; Paupe et al., 2018), 
maintaining redox balance (Pelicano et al., 2006; reviewed by Trachootham et al., 
2008; Handy et al., 2012), influencing cellular growth and cell death (Shimizu et al., 
1999, reviewed by Green et al., 1998; Kroemer et al., 2000; Antico Arciuch et al., 
2012), maintaining metabolic homeostasis (reviewed by Cheng et al., 2013) and 
signaling (reviewed by Chandel, 2014 and 2015). In eukaryotic cells, mitochondria 
and chloroplasts (in plants and photosynthetic algae) are the only organelles that 
contain their own DNA, apart from the nucleus (Lodish et al., 2000). 
 
2.2. Evolutionary origins of mitochondria 
A widely accepted theory for the origin of mitochondria in eukaryotic cells is the 
endosymbiotic theory. It postulates that an event occurred during or after the 
appearance of molecular oxygen in the Earth’s atmosphere, wherein aerobic proteo-
bacteria were engulfed by host microbes, believed to be related to present-day 
archaea, that could ferment glucose, resulting in a symbiotic relationship (Margulis, 
1981; Gray et al., 1999).  
 
2.3. Mitochondrial structure and biogenesis 
Palade (1952) first reported the fine structure of mitochondria. In albino rat tissues, 
mitochondria were observed as either circular or oval-shaped organelles with a 
diameter varying between 0.2 to 1 μm, depending on the cell type. The first 
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observations of mitochondria in rat tissues and human blood leucocytes showed that 
mitochondria are a double-membraned structure, where the outer membrane is 
separate from the inner membrane, which surrounds an internal matrix (Palade, 1952; 
Low, 1956; schematic shown in figure 1). The mitochondrial membranes consist of 
phospholipid bilayers with many protein complexes embedded in them. Such 
complexes facilitate various functions, ranging from transportation of molecules 
between mitochondria and the cytosol of the cell, to the generation of ATP through 
OXPHOS (reviewed by Neupert et al., 2007; see section 2.3.1 below). 
 
2.3.1. Outer membrane 
The outer mitochondrial membrane (OMM) contains two major protein complexes; 
the translocase of the outer membrane (TOM) and the sorting and assembly 
machinery (SAM), as well as voltage-dependent anion channels (VDAC, porin). 
These membrane protein complexes facilitate the transport of all relevant molecules, 
including precursor proteins and ions. Smaller molecules, that are less than 5 kDa, 
are able to diffuse through VDAC but protein molecules larger than 5 kDa can only 
be transported via the TOM and SAM complexes (Wiedemann et al., 2003; Bayrhuber 












Matrix ATP synthase dimer 
Figure 1: Schematic representation of a cross-sectioned mammalian mitochondrion. ATP synthase
(complex V, F1-Fo-ATPase), IMM – inner mitochondrial membrane, IMS – intermembrane space,
mtDNA – mitochondrial DNA, OMM – outer mitochondrial membrane, Respiratory complexes: complex 
I (NADH:ubiquinone oxidoreductase); complex II (succinate:ubiquinone oxidoreductase); complex III
(ubiquinol-cytochrome c oxidoreductase) and complex IV (cytochrome c oxidase), SAM - the sorting
and assembly machinery, TIM - the translocases of the inner membrane, TOM - the translocase of the
outer membrane, VDAC - voltage-dependent anion channels.  
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2.3.2. Inner membrane 
The first electron-microscopic images of mitochondria revealed invaginations of the 
inner mitochondrial membrane (IMM), termed cristae (Palade, 1952; Low, 1956). The 
cristae increase the surface area of the IMM and their number varies according to the 
functional activity of mitochondria (reviewed by Cogliati, 2016). Like the OMM, protein 
transfer through the IMM is mediated by protein complexes denoted as the 
translocases of the inner membrane (TIM) (reviewed by Neupert et al., 2007). Unlike 
the OMM, the transfer of molecules across the IMM requires an electrical membrane 
potential (ΔΨ). The cristae of the IMM contain the assembled respiratory chain 
complexes, as well as ATP synthase. 
 
2.3.3. Intermembrane space and matrix 
The space between the OMM and IMM is denoted as the intermembrane space (IMS). 
The IMS is an aqueous compartment that acts as a bridge between the cytoplasm of 
the cell and the mitochondrial matrix. The IMS contains protein molecules and 
metabolites in transit between the IMM and OMM, and has a lower pH than the 
innermost compartment of mitochondria, the matrix. The mitochondrial matrix, which 
is also an aqueous compartment, contains mitochondrial DNA (mtDNA), enzymes for 
the citric acid cycle (TCA cycle) and beta-oxidation of fatty acids, as well as proteases, 
ribosomes and ions. The mitochondrial matrix generally has a high pH, 7.9 to 8.0 
(Llopis et al., 1998), which generates the electrochemical gradient for ATP synthesis.  
The mitochondrial matrix is the site of numerous enzymatic reactions, including 
several major metabolic pathways, such as those already mentioned above, as well 
as the urea cycle (in liver), plus the molecular machineries for mtDNA replication and 
transcription and protein synthesis. 
 
2.3.4. Mitochondrial biogenesis and distribution 
Mitochondrial biogenesis is the process of growth and/or division of existing 
mitochondria. The mitochondrial mass (Robin and Wong, 1988), and their dynamics 
and spatial arrangement, i.e. networks vs fragment (reviewed by Kuznetsov et al., 
2009), varies between cell types but are generally consistent within a given cell type. 
Mitochondrial proteins are encoded in both mtDNA and nuclear DNA (nDNA), 























double stranded in most species, with the exception of a few unicellular eukaryotes 
which contain linear mtDNA, e.g. Tetrahymena, Paramecium (Borst, 1977), 
Chlamydomonas, Pandorina, Polytomella, Sphaerellopis, Candida, Theileria and 
Lobochlamys (reviewed by Nosek et al., 1998; Smith et al., 2010). The human 
mitochondrial genome is 16.6 kb long and encodes 37 genes in total, namely 22 
tRNAs (transfer RNAs), 13 proteins (all of them being subunits of OXPHOS 
complexes) and 2 rRNAs (ribosomal RNAs) (figure 2). However, the majority of 
proteins required for mitochondrial biogenesis and function, approximately 1500 
(Lopez et al., 2000), including all other subunits of the OXPHOS complexes, are 
encoded in the nDNA, synthesized in the cytosol and imported into the mitochondria.  
Unlike nDNA, mtDNA does not contain introns and the non-coding sequences are 
present in a single region, referred to as the control region. The control region is 
approximately 1.1 kb, located between the coding sequences of tRNA(Pro) and 
tRNA(Phe), and contains the origin of replication of the heavy strand (OH), the 
displacement-loop (D-loop) region, and the transcriptional start sites of both strands, 
conventionally denoted as heavy and light, based on their buoyant densities. Since 
mitochondria are the major source of ATP, especially in muscle and heart, increased 
physical exercise has been shown to increase mitochondrial biogenesis (Holloszy, 
1967). Apart from physiological stress, many other factors influence mitochondrial 
Figure 2: Schematic representation of human mitochondrial DNA. Genes encoding proteins, rRNA and 
tRNA are indicated along with their respective positions (segments are not to actual scale). The genes 
encoding specific tRNAs are represented by their cognate amino acid (e.g. Ser – Serine) and, where
appropriate, the specific codon group decoded. OH and OL are the origins of heavy- and light-strand
replication, respectively. HSP and LSP are the transcription promoters for the heavy- and light-strand,
respectively. Note – strand assignments not shown for protein coding genes, of which ND6 is opposite
to all the others.  
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biogenesis, such as, reactive oxygen species (ROS), hypoxia, Ca2+ homeostasis, 
inflammation and thermogenesis (reviewed by Nisoli et al., 2006, Jornayvaz et al., 
2010, Dominy et al., 2013,  Wenz, 2013, Suliman et al., 2015, Cherry et al., 2015). 
Within the cell, mitochondria are generally observed as interconnected organelles 
that form a network (Lewis & Lewis, 1914). However, mitochondria are also highly 
dynamic and constantly change their shape and network connections depending on 
the physiological needs of the cell (reviewed by Westermann, 2010). Mitochondrial 
network formation and granulation is facilitated by fusion and fission reactions, 
respectively. In mammals, mitochondrial fusion is mediated by mitofusin I (MFN1), 
mitofusin II (MFN2) and optic atrophy I (OPA1) proteins, where MFN1 and 2 mediate 
outer membrane fusion and OPA1 mediates inner membrane fusion. Mitochondrial 
fission is mediated by dynamin-1-like protein (DMN1L, also commonly known as 
DRP1) (reviewed by Westermann, 2010; Lackner, 2014). A balance between 
mitochondrial fission and fusion is essential to maintain the cell in a healthy state and 
a shift towards either direction may affect metabolic and energy homeostasis, unless 
such a shift is dictated by the state of the cellular activity (reviewed by Westermann, 
2010). 
 
2.4. Mitochondrial functions 
One of the most widely studied functions of mitochondria is ATP production via 
OXPHOS, energized by the electron transport chain (ETC). Since my project has 
largely involved studying ETC defects in disease conditions, I will primarily focus on 




OXPHOS is the biochemical process involving the re-oxidation of the primary electron 
carriers of metabolism, NADH and FADH2, which drives the phosphorylation of ADP 
to ATP in the mitochondria. The protein complexes involved in this pathway are all 
located in the IMM. Mitchell (1961) first proposed a model for the process of ATP 
formation in mitochondria, known as the chemiosmotic hypothesis. The reduced 
electron carriers, NADH and FADH2, which are produced by the major metabolic 
pathways in mitochondria, are oxidized by the first two ETC complexes. 
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NADH:ubiquinone oxidoreductase (complex I, cI) oxidizes NADH, whilst FADH2 is an 
intermediate in the reactions catalyzed by succinate:ubiquinone oxidoreductase 
(succinate dehydrogenase, complex II, cII) and other mitochondrial dehydrogenases. 
The protons released in these oxidation reactions are pumped from the mitochondrial 
matrix into the IMS, whilst the electrons are shuttled through subsequent steps of the 
ETC, ultimately reducing oxygen to water through a series of protein complexes. The 
flow of electrons and subsequent proton pumping creates an electrical potential and 
a pH gradient across the IMM that is used to drive ATP synthesis via the F1-Fo-
ATPase (ATP synthase, complex V, cV). A schematic diagram of the OXPHOS 
pathway is shown in figure 3. 
 
2.4.2. Electron transport chain (ETC) 
As well as cI and cII, the mitochondrial ETC includes two additional multi-subunit 
enzyme complexes, namely ubiquinol-cytochrome c oxidoreductase (complex III, cIII) 
and cytochrome c oxidase (complex IV, cIV), as well as 2 mobile intermediate electron 
carriers – ubiquinone, also known as coenzyme Q (CoQ) and cytochrome c. These 
'standard' ETC components are prevalent in the majority of eukaryotes. However, 
many species, including most plants and fungi, also contain alternative enzymes to 
Figure 3: Schematic representation of the OXPHOS pathway. Electrons obtained from the oxidation of 
NADH and FADH2 by cI and cII, respectively, are transferred to cIII via ubiquinone (CoQ), which is then 
transferred to cIV via cytochrome c. cIV transfers the electrons to molecular oxygen to convert it into 
water. In this process, cI, cIII and cIV pump protons to the IMS. The resulting proton motive force is











































oxidize NADH and reduce O2 to water, which I will describe later in this chapter 
(2.4.2.8). For a comprehensive review of the structure and organization of 
mitochondrial respiratory complexes, see review by Lenaz and Genova (2010). 
 
2.4.2.1. Complex I 
Complex I is the largest of the respiratory chain complexes containing 45 subunits, 
with a combined molecular mass of approximately 1000 kDa in mammals (Hirst et al., 
2003, Caroll et al., 2006). Only 7 of the 45 subunits are encoded in the mtDNA, with 
the remainder encoded by nDNA. The nuclear-coded cI polypeptides are imported 
into the mitochondria for cI assembly. The fully assembled protein complex is L-
shaped (Guenebaut et al., 1997; Radermacher et al., 2006), with one arm embedded 
in the inner membrane and the other protruding into the mitochondrial matrix. 
Oxidation of NADH to NAD+ results in the transfer of electrons to ubiquinone and 4 
protons to the IMS, as represented by the following reaction scheme. 
 
NADH + H+ + Q + 4H+matrix → NAD+ + QH2 + 4H+IMS 
 
In the above equation, Q is ubiquinone and QH2 is ubiquinol, the reduced form of 
ubiquinone. Several compounds can inhibit the activity of cI: for example, the classical 
inhibitor rotenone. The majority of known cI inhibitors target the NADH-Q reductase 
activity (reviewed by Esposti, 1997). 
 
2.4.2.2. Complex II 
Mitochondrial cII is the only protein complex of the ETC whose subunits are all 
nuclear-coded. It consists of 4 subunits: SDHA, SDHB, SDHC and SDHD. SDHA and 
SDHB protrude out into the matrix whereas SDHC and SDHD are embedded in the 
IMM. cII catalyzes the conversion of succinate to fumarate, one of the reactions of 
the TCA cycle, resulting in the reduction of FAD to FADH2 in the flavoprotein subunit 
SDHA. The electrons obtained from this step are passed to ubiquinone via three iron-
sulfur (Fe-S) clusters, reducing it to ubiquinol. The biochemical reaction catalyzed by 
cII is therefore described by the following scheme: 
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Succinate + FAD → Fumarate + FADH2 + 2e- 
Q + 2e- + 2H+ → QH2  
 
Unlike cI, the reduction of quinone by cII does not involve proton translocation into 
the IMS. There are several inhibitors for cII that target the quinone-binding site, such 
as 2-thenoyltrifluoroacetone (TTFA), 3-methyl-carboxin and 2-n-heptyl-4-
hydroxyquinoline-N-oxide (HQNO) (reviewed by Hägerhäll, 1997). Malonate is also a 
competitive inhibitor of cII (Thorn, 1953) as it binds to the active site of SDHA, 
preventing succinate binding. 
 
2.4.2.3. Ubiquinone 
Ubiquinone (CoQ) is a naturally synthesized, lipid-soluble coenzyme that interacts 
with three mitochondrial respiratory complexes, cI, cII and cIII. It also contributes to 
the regulation of the NADH/NAD+ ratio and to antioxidant activity, as well as 
influencing cell growth and proliferation (reviewed in Bentinger et al., 2010). The 
polyprenilated sidechain of CoQ differs depending on the species, for example, 
rodents have predominantly CoQ9 (9-carbon side chains) whereas humans have 
almost exclusively CoQ10 (10-carbon side chain, reviewed by Fabra et al., 2016). 
 
2.4.2.4. Complex III 
Mitochondrial cIII consists of 11 subunits of which only one is encoded in the mtDNA 
(reviewed by Lenaz and Genova, 2010). The enzyme catalyzes the transfer of 
electrons from ubiquinol to oxidized cytochrome c (Cyt c), and pumps 4 protons to 
the IMS in a reaction that may be summarized thus: 
 
QH2 + 2Cyt c oxidized + 2 H+matrix → Q + 2Cyt c reduced + 4H+IMS 
 
The molecular mechanism of electron transport from ubiquinol to cytochrome c by cIII 
is termed the Q cycle, described in detail by Berg et al. (2002). Mitochondrial cIII is 
also known as the cytochrome bc1 complex since it contains a total of three heme 
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groups, heme bL (low affinity heme), heme bH (high affinity heme) and a c-type heme. 
In addition, cIII contains the Rieske iron-sulfur protein, which stabilizes the complex 
in the reduced state (reviewed by Berg et al., 2002). The majority of cIII inhibitors 
target Q cycle function, including the commonly used agent antimycin A (reviewed by 
Lenaz and Genova, 2010). 
  
2.4.2.5. Cytochrome c 
Cytochrome c carries electrons from cIII to cIV by bridging the cytochrome c1 moiety 
and the CuA centre of cIV (Berg et al., 2002). It is a small, nuclear encoded, water-
soluble hemoprotein (approx. 12.5 kDa), loosely bound to the IMM on the IMS side. 
Apart from its function in the ETC, the protein also participates in several other 
processes, including modulating ROS levels, apoptosis and cardiolipin peroxidation 
(reviewed by Ow et al., 2008; Huttemann et al., 2011).  
 
2.4.2.6. Complex IV 
Cytochrome c oxidase is the terminal enzyme of the respiratory pathway that 
catalyzes the conversion of molecular oxygen to water. The enzyme complex consists 
of 13 subunits of which 3 are encoded in the mtDNA. The enzyme includes 2 heme 
groups, heme a and heme a3, and 2 copper centers, CuA and CuB. The oxygen 
molecule binds to heme a3 where, with the addition of 4 protons, it is converted to 2 
water molecules, in the process pumping 4 protons to the IMS (Berg, 2002) as 
summarized by the following scheme:  
 
4Cyt creduced + O2 + 8H+matrix → 4Cyt coxidised + 2H2O + 4H+IMS 
 
The intermediate steps in the conversion of oxygen to water theoretically involve the 
generation of highly reactive superoxide anions (O2-) and/or peroxides (O22-), which 
might escape the enzymatic complex and induce oxidative damage. However, the 
reaction mechanism effectively prevents their release, although inhibition of cIV could 
still lead to excess ROS production at upstream sites in the ETC, for which ROS 
detoxifying systems are required. cIV can be inhibited by cyanide, carbon monoxide 
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(CO) and azide, all of which target the oxygen binding site of the enzyme (reviewed 
by Lenaz and Genova, 2010). 
 
2.4.2.7. Complex V 
The ETC ends with the transfer of electrons to molecular oxygen via cIV. However, 
the protons pumped into the IMS by cI, cIII and cIV form a proton gradient that drives 
the generation of ATP from ADP, catalyzed by cV (Mitchell, 1961). cV can therefore 
be considered as the terminal enzyme of the OXPHOS system. It consists of two 
major sub-complexes, Fo (the ‘oligomycin fraction’), which conducts protons from the 
IMS to the matrix, and the soluble F1 ('fraction 1'), which protrudes into the matrix and 
is the catalytic moiety that converts ADP to ATP using the energy generated from the 
proton gradient (Stock et al., 1999; Watt et al., 2010). The proton gradient drives the 
rotation of the motor units of cV, which are the c ring of the Fo and the central stalk, 
comprising F1 subunits ɣ, ɛ and δ (reviewed by Stewart et al., 2014). Briefly, the 
catalytic reaction of cV can be described as follows: 
 
~3-5H+IMS + ADP + Pi → ATP + ~3-5H+matrix 
 
In the above equation, ADP is adenosine diphosphate and Pi is inorganic phosphate. 
The number of protons required to generate one molecule of ATP depends on the 
size of the Fo region (the number of subunits in the c ring) and for every 360° rotation 
of the motor elements, 3 molecules of ATP are generated (Watt et al., 2010). Complex 
V can be inhibited using oligomycin (A), which targets the Fo segment (reviewed by 
Nicholls et al., 2013). 
 
2.4.2.8. Alternative respiratory enzymes 
Apart from the standard ETC protein complexes, many species, including most 
plants, protists and fungi, but not mammals, contain alternative enzymes capable of 
replacing cI and cIII plus cIV, namely alternative NADH dehydrogenases (NDH) and 
alternative oxidases (AOX), respectively. These alternative enzymes perform 
catalytic reactions similar to the standard ETC enzymes but do not translocate 








































active (reviewed by Lenaz et al., 2010). The alternative enzymes are also resistant to 
the common inhibitors of cI, cIII and cIV. Since my thesis focuses on studying the 
effect of AOX expression in mammals,the biology of AOX is described in greater detail 
in the following section.  
 
2.4.2.9. Alternative oxidase 
As mentioned, AOX is an alternative terminal oxidase that can bypass the catalytic 
activity of cIII and cIV by transferring electrons directly from ubiquinol to oxygen, 
reducing it to water (figure 4).  
Genes for AOX are present in plants, and are widely distributed in fungi, protists and 
invertebrates (McDonald et al., 2004). AOX is a nuclear-coded, diiron carboxylate 
enzyme with a molecular weight of approximately 35 kDa, that is bound to the IMM 
facing the matrix side (Moore et al., 1995, Siedow et al., 1995, reviewed by Berthold 
et al., 2003). The catalytic activity of AOX is resistant to respiratory inhibitors such as 
cyanide, antimycin A, and azide. Unlike cIII and cIV, electron transport by AOX does 
not involve proton translocation and the energy is rather dissipated as heat in a 
thermogenic process. Organisms harboring AOX benefit from branched respiration 
under conditions where cIV is either slowed down or defective, and when ADP levels 
are low in mitochondria, for example, during photosynthesis in plants. AOX activity 
has also been shown, in plants, to lower ROS production in mitochondria (Maxwell et 
Figure 4: Schematic representation of the ETC showing AOX activity. AOX is activated under conditions 
of cytochrome pathway dysfunction of the ETC or increased accumulation of reduced CoQ. When
active, AOX catalyzes the reduction of oxygen to water in a non-proton-motive reaction. Thus, cI is the 
only proton pump when AOX is fully active in place of cIII and cIV. 
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al., 1999), to induce thermogenesis (Wagner et al., 2008), and prevent over-reduction 
of quinones (Yoshida et al., 2010). Several independent observations, in plants, fungi 
and protists have indicated that AOX can maintain respiration under conditions of 
cytochrome pathway impairment due to genetic or environmental causes (Albury et 
al., 1996, reviewed by McDonald & Gospodaryov, 2019). Although beneficial effects 
and widespread presence of the enzyme have been described in sessile animals, 
AOX is not present in vertebrates, as a consequence of evolutionary loss of the AOX 
gene. Since cIII has a higher affinity for ubiquinol than AOX, the AOX-mediated 
alternative respiratory pathway does not compete with the traditional ETC pathway 
under steady-state conditions (Bahr et al., 1973). Therefore, AOX is enzymatically 
active and contributes to electron flow in the ETC only when the concentration of 
ubiquinol is abnormally high, indicating a respiratory chain defect downstream of 
ubiquinol. This unique property of AOX made it a suitable candidate to be 
transgenically expressed in mammals with a functional cytochrome pathway, yet 
minimizing any detrimental effects that might result from by-passing the OXPHOS 
system under standard physiological conditions.  
 
2.4.2.10. ROS production in the ETC 
Since the majority of the inhaled oxygen is metabolized in the ETC, the ETC is also 
a major source of ROS production. In the ETC, single electron reduction of oxygen 
results in the formation of oxygen radicals, such as the superoxide anion (O2•−)ּ and 
the hydroxyl radical (OH•), as well as the nonradical molecules like hydrogen peroxide 
(H2O2), which are derived from superoxide anions. The catalytic reactions of ROS 
production can be described as following: 
 
O2 + e-  O2•− 
2O2•− + 2H+ → H2O2 + O2 
O2•− + H2O2 OH• + OH− + O2 
H2O2 + Fe2+ → OH• + OH− + Fe3+  
 
The superoxide anion and hydrogen peroxide are the two major ROS products of the 
ETC. Under physiological conditions about 0.2 - 2% of the electrons deviate from the 
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normal electron transfer pathway and result in ROS formation (reviewed by Zhao et 
al., 2019). In the ETC, cI and cIII are the major sites of ROS production (Brand, 2010).  
In cI, superoxides can be generated and passed into the matrix during both forward 
and reverse electron transfer via IF (FMN site) and the IQ (CoQ binding site), 
respectively (Treberg et al., 2011). However, ROS production via site IQ is of a higher 
magnitude than via site IF (Brand, 2010). Blocking the IQ site with rotenone results in 
a several-fold increase in ROS production from the site IF (reviewed by Murphy, 2009; 
Brand, 2010). Likewise, reverse electron flow through cI, arising from an over-
reduced Q-pool, results in electron leak via site IQ, and blocking this site with rotenone 
significantly diminishes the superoxide production (Brand et al., 2016).  
In cIII, superoxide is mainly generated via the IIIQo site (semiquinone at center o). 
When exposed to the cIII inhibitor, antimycin A, electron transfer from heme bL to the 
quinone at center i is blocked, leading to a buildup of semiquinone at center o that 
can readily reduce O2 to superoxide (Cape et al., 2007; Brand, 2010). Unlike cI, cIII 
can release superoxide into both the matrix and the IMS (Brand, 2010). 
Other sites of ROS production in mitochondria are glycerol 3-phosphate 
dehydrogenase, the electron transferring flavoprotein: Q oxidoreductase (ETFQOR) 
of fatty acid beta oxidation, pyruvate and 2-oxoglutarate dehydrogenases, as well as 
negligible amounts from cII (Brand, 2010). 
Although mitochondria are a major source of ROS production in the cell, 
paradoxically, they are also a major target of ROS-mediated damage, which can 
affect mtDNA, proteins and lipids. Such deleterious effects of ROS can be prevented 
by various antioxidant systems. For instance, superoxides are converted into a more 
stable H2O2 by a family of metalloenzymes called superoxide dismutases (SOD, 
Fridovich, 1995). Superoxides produced in the matrix are processed by manganese-
superoxide dismutase (Mn-SOD; SOD2) and those produced in the IMS are 
processed by copper-zinc-superoxide dismutase (CuZnSOD; SOD1, Fridovich, 
1995). Other relevant antioxidants in the cell are glutathione peroxidases (GPXs), 
peroxiredoxins (PRXs) and catalases, which convert H2O2 to H2O.  
  
2.4.3. Metabolic pathways 
As mentioned above, major metabolic pathways in mitochondria are the tricarboxylic 
acid (TCA, Krebs, citric acid) cycle, fatty acid oxidation (β-oxidation) and the urea 
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cycle. The TCA cycle is an oxidative aerobic pathway, which results in the oxidation 
of acetyl-CoA to carbon dioxide and water, with the concomitant production of ATP 
via the OXPHOS system.  Acetyl-CoA is synthesized mostly via three pathways; a) 
at the terminal step in carbohydrate metabolism, which begins with the translocation 
of pyruvate, a product of glycolysis, from the cytosol to the mitochondrial matrix, 
where it is oxidized to acetyl-CoA by the pyruvate dehydrogenase complex; b) fatty 
acid oxidation, which takes place in the mitochondrial matrix and c) catabolism of 
some specific amino acids, for example, tryptophan, leucine and isoleucine. Acetyl-
CoA is the substrate for the TCA cycle. After a series of enzymatic reactions it finally 
gives rise to oxaloacetate, which is required for the incorporation of the next molecule 
of acetyl-CoA to form citrate, the first step in the TCA cycle. Oxaloacetate is therefore 
regenerated by the cycle. Two major rate-limiting factors of the TCA cycle are a) the 
concentration of substrates - acetyl-CoA and oxaloacetate, which participate in the 
first step of the TCA cycle, and b) the activity of citrate synthase, which can be 
regulated by the concentration of ATP (Krebs, 1970). The TCA cycle produces ATP 
mainly through OXPHOS, via the generation of NADH and FADH2. For every acetyl-
CoA molecule metabolized, three molecules of NADH and one molecule of FADH2 
are produced in the TCA cycle. 
Fatty acid oxidation breaks down fatty acids to generate acetyl-CoA. Fatty acids are 
first activated in the cytosol by the enzyme acyl-CoA synthetase to form fatty acyl-
CoA, which can then be imported into the mitochondrial matrix indirectly, through the 
carnitine shuttle. This transport involves intermediate steps catalyzed by the carnitine 
palmitoyltransferases CPT-I and CPT-II. Fatty acyl-CoA then undergoes a cyclical 
four-step reaction producing acetyl-CoA, NADH and FADH2 in each cycle. The 
pathway is also called β-oxidation because it involves the removal of two carbon units 
at the beta position of the fatty acid in each cycle (reviewed by Schulz, 1991). Fatty 
acid oxidation also occurs in peroxisomes, which handle the first steps in the 
degradation of very long chain fatty acids. 
Amino acid breakdown produces large quantities of ammonia (NH3), which is a toxic 
metabolite, and is primarily processed in mammals in the liver into a non-toxic form, 
urea. Urea is released into the bloodstream, which is excreted by the kidneys as urine. 
The metabolic pathway of conversion of ammonia into urea is termed the urea cycle, 
which was first proposed by Krebs (1932). The urea cycle involves five enzymatic 
steps of which the first two occur in the mitochondria. Briefly, ammonia derived from 
the mitochondrial matrix is converted to carbamoyl phosphate, which reacts with 
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ornithine to produce citrulline. Citrulline is translocated to the cytosol where it 
undergoes 3 more enzymatic reactions producing urea and ornithine as end products. 
Ornithine re-enters the mitochondrial matrix to initiate another cycle (Nelson et al., 
2017).  
All the above-mentioned metabolic pathways can function on their own, yet they are 
also closely interconnected (figure 5). For example, the end product of fatty acid 
breakdown, acetyl-CoA, feeds into the TCA cycle as a substrate and the by-products 
from these two pathways, NADH and FADH2 enter the OXPHOS pathway to generate 
ATP. Transamination of oxaloacetate, an intermediate product of the TCA cycle, 
produces aspartate, which feeds into the urea cycle. Likewise, an intermediate 
product of the urea cycle, fumarate, produced from arginosuccinate, feeds into the 
TCA cycle where it is converted to malate. Therefore, dysfunction in any one of these 
pathways might, theoretically, affect metabolic homeostasis within mitochondria, 
ultimately affecting net ATP production and other important mitochondrial functions. 
 
2.5. Mitochondrial diseases 
Since ATP production is considered the major biological activity of mitochondria, the 
term mitochondrial disease is usually applied to cases with defective OXPHOS. 
Figure 5: A simplified schematic diagram representing the interconnected metabolic pathways in the 
mitochondria highlighting the TCA cycle, fatty acid oxidation and urea cycle. Due to the interconnected 
nature of the metabolic pathways, dysfunction in one might disturb metabolic homeostasis within the 
entire mitochondrion. As a consequence, mitochondrial function is affected, including net ATP



























These diseases are further classified into primary and secondary mitochondrial 
diseases, based on the underlying cause of the dysfunction. Primary mitochondrial 
diseases are caused by mutations in mtDNA or in nDNA genes that directly encode 
OXPHOS proteins, mitochondrial tRNA or rRNA, or other proteins that affect the 
OXPHOS pathway. Such mutations may be inherited from either one or both parents. 
In contrast, secondary mitochondrial diseases include pathological conditions that 
either arise due to germline mutations of non-OXPHOS genes or adverse 
environmental effects, for example, oxidative stress in the course of aging or 
associated with inflammatory response, that affect mitochondrial function. Thus, 
secondary mitochondrial diseases can be either inherited or acquired, whereas 
primary mitochondrial diseases are most commonly inherited (reviewed by Niyazov 
et al., 2016).  
Current estimates for the prevalence of mitochondrial disease mutations, including 
both mtDNA and nDNA genes encoding mitochondrial proteins, are 1 in 4300 in the 
UK, including non-symptomatic mutations (Gorman et al., 2015). Mitochondria 
contain thousands of copies of mtDNA per somatic cell, ranging from 1000 to 10000 
depending on the cell type. This may lead to the co-existence of both a normal and 
mutated mtDNA population within the same cell, referred to as heteroplasmy, which 
was first reported in patients suffering from mitochondrial myopathy (Holt et al., 1988). 
However, symptoms leading to disease generally occur only when the mutation load 
exceeds a particular threshold in the cell, which varies for different mutations and cell 
types. Conversely, the term 'homoplasmy' describes the condition where cells harbor 
identical mtDNA copies. Due to variations in the extent of heteroplasmy, 
mitochondrial diseases differ widely in age of onset, ranging from early childhood to 
late adulthood. They can affect a single organ (e.g. LHON) or multiple organs (e.g. 
GRACILE syndrome) (reviewed by Khan et al., 2015). 
In the heart muscle, the majority of ATP is produced by mitochondria. Thus 
mitochondrial diseases often present with cardiac involvement, especially 
cardiomyopathy, estimated to occur in 20 to 40% of children with mitochondrial 
diseases (Holmgren et al., 2003, Scaglia et al., 2004, reviewed by El-Hattab et al., 
2016). Mitochondrial disease patients with cardiomyopathy exhibit a higher rate of 
mortality (71%) at a very young age, compared to patients without (Holmgren et al., 
2003, Scaglia et al., 2004). Cardiomyopathies may also occur in patients with mtDNA 
mutations with no previously known connection to mitochondrial diseases. In such 
cases, cardiomyopathy may be the first or the sole clinical manifestation (reviewed 
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by Brunel-Guitton et al., 2015). On the other hand, due to the heterogeneous nature 
of mitochondrial diseases, the severity of symptoms and age of onset can vary 
between individuals. Therefore, cardiac involvement cannot, on its own, present a 
comprehensive picture of a mitochondrial disease (Catteruccia et al., 2015). 
 
2.5.1. Defective OXPHOS pathway 
Defective OXPHOS can have a wide range of adverse effects on the cell, including 
ATP deficiency, metabolic imbalance and excessive production of reactive oxygen 
species (ROS). Mutations in genes encoding subunits of OXPHOS protein complexes 
and/or its assembly factors account for several diseases. These can present either 
as a defect in a single multisubunit complex (e.g. GRACILE syndrome) or as a 
combined dysfunction of many complexes (e.g. most cases of mitochondrial 
cardiomyopathy), in either case giving rise to diverse clinical features. A list of some 
widely known mitochondrial diseases caused by defective OXPHOS complexes 
and/or their assembly factors are provided in table 1. 
Apart from mutations in genes encoding OXPHOS subunits mitochondrial dysfunction 
can also be due to: 
a) deletions in mtDNA – e.g. Kearns-Sayre syndrome (KSS, Zeviani et al., 1998), 
mitochondrial recessive ataxia syndrome (MIRAS, Hakonen et al., 2008), 
b) dysfunction of the mitochondrial protein synthesis machinery – e.g. 
mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MILASA), 
due to a mutation in the YARS2 gene (Riley et al., 2010), which encodes for 
the mitochondrial protein that catalyzes the aminoacylation of tyrosyl tRNA, 
c) disrupted mitochondrial dynamics – e.g. Charcot-Marie-Tooth diseases type 
2A (CMT2A) due to mutations in the mitofusin 2 gene (MFN2, Nicholson et 
al., 2008), which regulates mitochondrial fusion; or 
d) external factors like aging, diet, inflammation and many pharmacologic 
agents, such as statins, valporic acid, metformin and barbiturates (reviewed 




Table 1: List of widely known mitochondrial diseases and the dysfunctional OXPHOS complex 
associated with them. Online Mendelian Inheritance in Man (OMIM) IDs are provided for 
further information. For cardiomyopathy and encephalopathy, OMIM IDs of mitochondrial 
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2.5.2. Diagnosis of mitochondrial diseases 
Early diagnosis of mitochondrial diseases is very challenging due to; a) overlapping 
clinical presentations for a specific genotype, for example, the A3243G point mutation 
in mtDNA, which can lead to maternally inherited diabetes and deafness (MIDD), or 
MELAS, or chronic progressive external ophthalmoplegia (CPEO) and b) wide 
variations in the onset of symptoms, like in case of MELAS (reviewed by El-Hattab et 
al., 2015).  
A general roadmap for diagnosing mitochondrial diseases involves a series of 
evaluations, including biochemical assessment of blood, cerebrospinal fluid and urine 
samples, histological assessment of muscle biopsy, evaluation of heart function by 
echocardiography and of pathological signs in the brain by magnetic resonance 
imaging (MRI), genetic screening (whole exome sequencing) and investigation of 
family history for pathological symptoms and routine follow-up of clinical symptoms 
(Parikh et al., 2014; reviewed by Dimmock et al., 2018).  
Despite advances in diagnostic tools and methods, challenges remain in providing 
accurate diagnoses of mitochondrial diseases. These are either due to limitations in 
testing methods, including challenges with tissue processing and variability of 
methods between labs, or due to a lack of in-depth understanding of the genotype-
phenotype variations (reviewed by Parikh et al., 2019). 
 
2.5.3. Current therapeutic options for mitochondrial diseases 
No cure is currently available for any mitochondrial disease. Existing therapeutic 
strategies aim to control specific symptoms and disease progression. These 
therapies include increasing aerobic exercise (Jeppesen et al., 2006), diet 
interventions (Ahola et al., 2010; Joshi et al., 2009), supplementation of vitamins such 
as riboflavin (Bugiani et al., 2006) or other organic compounds, e.g. creatine 
monohydrate (Tarnopolsky et al., 1997), carnitine (Gimenes et al., 2015) and 
idebenone (Rudolph et al., 2013), and redox agents such as lipoic acid and 
glutathione (reviewed by El-Hattab et al., 2017). For comprehensive recent reviews 
see Parikh et al. (2009), Suomalainen (2011) and El-Hattab et al. (2017). 
A lack of accurate pathophysiological knowledge about the majority of mitochondrial 
diseases is another major reason for the absence of available treatments. However, 
over recent decades, mitochondrial diseases have been studied extensively, leading 
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to the generation of many research models in order to gain deeper understanding of 
the underlying molecular mechanisms, to identify accurate biomarkers and/or 
potential drug targets for these diseases. 
 
2.6. The mammalian heart 
The heart is the first functioning organ to develop during embryogenesis (reviewed 
by Keller et al., 2007; Wittig et al., 2016). The mammalian adult heart is a complex 
muscle system made up of several different cell types. Its main purpose is to pump 
blood throughout the body, which is done by a continuous coordinated movement of 
the muscle referred to as heartbeats, or the cardiac cycle. In every cycle, the muscle 
contracts, referred to as the systolic phase of the cycle, so as to eject blood, followed 
by relaxation of the muscle, referred to as the diastolic phase of the cycle, to readmit 
blood into the heart. The contraction and relaxation of the muscle is carried out by the 
coordinated activity of cardiomyocytes, which account for approximately 30% of total 
cells, and occupy 70-85% of the total volume in the mammalian heart (Pinto et al., 
2016: cited in Zhou et al., 2016). Apart from cardiomyocytes, the heart comprises 




Adult cardiomyocytes can have 1-16 nuclei depending on the species (reviewed by 
Botting et al., 2012) and, in most mammals, they do not proliferate. Cardiomyocyte 
division occurs during embryogenesis until a few days after birth. For instance, in 
mice, cardiomyocyte proliferation continues until 7 days after birth, after which the 
majority of cardiomyocytes are terminally differentiated and the heart loses its 
potential to regenerate (Soonpaa et al., 1996, Porrello et al., 2011). In rodents, 
terminal differentiation is marked by binucleation of the cells, whereas in humans, the 
majority of terminally differentiated adult cardiomyocytes (74%) are mononucleated 
while only 25% are binucleated cells (Olivetti et al., 1996; reviewed by Bottling et al., 
2012). DNA synthesis in the cardiomyocytes occurs in two distinct phases, one during 
embryogenesis resulting in cell division and the other after birth, resulting in nuclear 
but not cell division (Soonpaa et al., 1996). Cardiac regeneration has been observed 
in amphibians and fish following mechanical incisions of the ventricular apex region 
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(Oberpriller et al., 1974; Becker et al., 1974; Poss et al., 2002), but this is very limited 
or absent in most mammals, including humans, under healthy conditions. However, 
under pathological conditions such as ischemia and chronic hypoxia, the adult heart 
switches to a ‘fetal-like’ condition indicated by triggered expression of specific 
transcription factors and their target genes, which normally are highly expressed 
during embryonic development, as well as metabolic adaptations such as the 
upregulation of glycolysis (reviewed by Taegtmeyer, 2010). This can be viewed as an 
alternative intracellular tissue renewal strategy operating after birth, as opposed to 
proliferation at the cellular level.  
 
2.6.2. Metabolism in the healthy heart 
The fetal heart is predominantly dependent on glucose and lactate for energy 
production, but after birth, a metabolic switch to fatty acid oxidation occurs in 
mammals (Bartelds et al., 2000). The metabolic switch is a result of metabolite 
availability and a rapid increase in myocardial energy demand. The switch from a 
relatively hypoxic environment during fetal development to oxygen-rich conditions 
after birth has been shown to increase mitochondrial biogenesis and alter 
mitochondrial morphology (Neary et al., 2014). The post-natal increase in 
mitochondrial volume is accompanied by an increase in the expression of about one-
third of all mitochondrial proteins (Pohjoismäki et al., 2012). Investigation of rat hearts 
at different stages showed evidence for an upregulation of mitoribosomal proteins 
and other components of the mitochondrial translation machinery at 10 days post-
natal (P10), whereas the expression of OXPHOS and fatty-acid oxidation proteins 
was triggered only at later stages (Pohjoismäki et al., 2012). The increase in 
mitochondrial biogenesis, at P10 also results in increased oxidative stress, leading to 
mtDNA damage, and concomitant upregulation of DNA repair proteins (Pohjoismäki 
et al., 2012). In human cardiomyocytes, the fetal to adult transition is accompanied 
by an approximately 2 fold increase in mitochondrial mass, although mtDNA copy 
number is relatively similar between the two developmental stages (Pohjoismäki et 
al., 2013). Additionally, proteins involved in mitochondrial transcription and translation 
are abundant in fetal cardiomyocytes, whereas proteins involved in the ETC and fatty-
acid oxidation are more abundant in adult cardiomyocytes (Pohjoismäki et al., 2013). 
The energy pool in adult heart consists of ATP and phosphocreatine (PCr). PCr is 
generated by the transfer of a phosphate group from ATP to creatine, catalyzed by 
creatine kinase inside mitochondria (mtCK). PCr readily moves through the 
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mitochondrial membranes and can be rapidly metabolized to regenerate ATP from 
ADP in the cytosol, catalyzed by cytosolic creatine kinase. The majority of cardiac 
ATP is generated from fatty acid oxidation, although glucose, lactate, amino acids 
and ketone bodies can serve as alternate fuels (reviewed by Doenst, et al., 2013). 
The heart has a high rate of ATP hydrolysis resulting in complete turnover of the ATP 
pool every 10 seconds under normal conditions. Most of the ATP in cardiomyocytes 
(approx. 60 to 70%) is used to power contraction, whilst the remainder primarily 
facilitates ion exchange through the sarcoplasmic reticulum (reviewed by Stanley et 
al., 2005). 
 
2.6.3. Heart mitochondria 
In adult heart, mitochondria provide about 90% of the ATP and constitute about 20 to 
40% of cellular volume in cardiomyocytes (Barth et al., 1992). Proper mitochondrial 
function, including ATP production and maintenance of Ca2+ homeostasis, is essential 
for contraction and relaxation of cardiomyocytes. In adult cardiomyocytes, 
mitochondria are segregated into three main locations, namely underlying the 
sarcolemma (sub-sarcolemmal mitochondria, SSM), between myofibrils (interfibrillar 
mitochondria, IFM) and around the nucleus (perinuclear mitochondria). The IFM are 
tightly packed, arranged in rows and in close contact with myofibrils and the 
sarcoplasmic reticulum. On the other hand, the SSM are distributed below the 
sarcolemma and are relatively loosely packed. Due to their close proximity to the 
sarcoplasmic reticulum and T-tubule, and tight contact with myofibrils, IFM are 
important for buffering Ca2+ and providing ATP for the contractile system. In contrast, 
SSM are important for active transport of metabolites and electrolytes across the 
sarcolemma (Palmer et al., 1977; Hollander et al., 2014). The IFM and SSM are both 
morphologically and biochemically different. For instance, the oxidative rate of IFM is 
1.4 to 1.7 times higher than that of SSM in rat cardiomyocytes (Palmer et al., 1977; 
reviewed by Pohjoismäki et al., 2017).  
 
2.6.4. Heart failure 
Heart failure can occur when the heart muscle weakens and fails to pump blood 
effectively (systolic failure) or stiffens and fails to relax, thereby affecting filling blood 
re-entry (diastolic failure). Heart failure can be classified into three main types, based 
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on ejection fraction; heart failure with reduced ejection fraction (HFrEF), heart failure 
with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection 
fraction (HFmrEF). Ejection fraction is measured using echocardiography or MRI and 
refers to the amount of blood ejected out of the left ventricle during each contraction. 
According to the American Heart Association (AHA), the ejection fraction of healthy 
individuals is in the range of 50 – 70%, whilst 41 – 49% is considered borderline and 
less than 40% is classified as reduced ejection fraction, which may lead to symptoms 
becoming noticeable. In conditions of HFpEF, the ejection fraction may still be normal 
(preserved) even though patients are diagnosed with heart failure. Symptoms of heart 
failure include fatigue, shortness of breath (dyspnea), retention of fluid in body tissues 
and altered heartbeat rates. In addition, heart failure is considered a cumulative 
disorder, where the initial stages are usually asymptomatic due to physiological 
compensatory mechanisms, for example, cardiac hypertrophy (enlargement of 
ventricles). However, under prolonged cardiac stress, the same mechanisms could 
lead to ventricular remodeling and compromised heart function (reviewed by Stanley 
et al., 2005 and Rosca et al., 2013).  
Cardiomyopathy is a disorder of the heart muscle, and is one of the many causes of 
heart failure. Four major kinds of cardiomyopathies have been described: a) dilated 
cardiomyopathy, a condition where the heart walls are stretched; b) hypertrophic 
cardiomyopathy, a condition arising due to thickening of the ventricular walls; c) 
restrictive cardiomyopathy, a condition where the walls become rigid and d) 
arrhythmogenic right ventricular cardiomyopathy, caused by the replacement of 
muscle cells with fibrous and fatty tissue. Hypertrophic cardiomyopathy is the most 
common form of cardiomyopathy reported in patients with mitochondrial diseases 
(approximately 50%). Dilated cardiomyopathy can occur as a primary or secondary 
clinical manifestation following hypertrophic cardiomyopathy, whereas restrictive 
cardiomyopathy is rarely reported in patients with mitochondrial diseases (Bates et 
al., 2012, Scaglia et al., 2004, reviewed by Brunel-Guitton et al., 2015; El-Hattab and 
Scaglia 2016). Inflammatory cardiomyopathy or myocarditis is a condition caused by 
inflammation of the cardiac tissue, predominantly due to viral infections or, in some 






2.6.5. Metabolic adaptation of failing heart 
Metabolic adaptation as a response to heart failure is a complex process. As indicated 
above, fatty acids are the predominant fuel for a healthy adult heart. However, under 
conditions of hypertrophy, glycolysis is upregulated and fatty acid oxidation is 
downregulated (Allard et al., 1994). Such a change in the metabolic fuel preference 
resembles the fetal period of cardiac development, where glucose oxidation is the 
major source of energy (figure 6).  
 
The accompanying changes in the gene expression pattern are referred to as the 
fetal gene program (Taegtmeyer et al., 2010). Studies on volume-overloaded heart 
showed decreased fatty acid oxidation along with marked drop in tissue carnitine 
levels (El Alaoui-Talibi et al., 1992). Since carnitine is required for the transport of 
long-chain fatty acids, such as palmitate, into mitochondria, a decrease in its level 
Figure 6: Changes in substrate utilization by the heart at different stages of growth and under
pathological conditions. Although the heart is capable of utilizing several different substrates for ATP 
production, the substrate preference changes with age, physiological and pathological conditions. The
developing heart has a strong preference for glycolysis and lactate oxidation for energy production, while
only minimal contribution is provided by fatty acid oxidation. In the adult heart, ATP is mainly produced 
via OXPHOS, fueled by fatty acids. The increased dependency on OXPHOS is also reflected by the 
increase in mitochondrial mass in the cardiomyocytes. Under pathological conditions, the heart switches 
to a fetal metabolic profile with increased reliance on glycolysis for energy production. Figure reprinted
with permission (Ritterhoff et al., 2017). 
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directly affects fatty acid oxidation in mitochondria. However, whether it is appropriate 
to consider this as metabolic adaptation or maladaptation depends on the stage and 
cause of heart failure. For example, in conditions of ischemia/reperfusion (Liu et al., 
2002) or diabetic cardiomyopathy, fatty acid oxidation is upregulated and glucose 
oxidation is decreased (reviewed by Fillmore et al., 2014). Although fatty acid 
oxidation is the primary fuel for ATP production in adult cardiomyocytes, an imbalance 
in the use of metabolic pathways results in decreased cardiac efficiency (reviewed by 
Fillmore et al., 2014). 
Oxygen concentration is another important factor in the progression of heart failure. 
The mammalian heart cannot generate sufficient energy under anaerobic conditions 
and thus requires a constant supply of oxygen of about 8-15 ml of oxygen per minute 
per 100 g of tissue at rest. Under conditions of ischemia, where tissues suffer 
diminished blood flow, or hypoxia, where oxygen supply is decreased, hypoxic-
inducible factor 1 alpha (HIF-1α) is stabilized as a consequence of metabolic 
maladaptation: for example, accumulation of succinate. HIF-1α regulates the 
expression of several genes, including genes involved in vascular remodeling, 
inflammation, angiogenesis, cell death and antioxidant mechanisms (reviewed by 
Giordano, 2005 and Howell et al., 2014). In addition, partial reduction of oxygen, i.e. 
transfer of only one or two electrons, results in the generation of ROS, which are 
generally considered as by-products of aerobic metabolism (figure 7; also see section 
2.3.2.10). However, when accumulated in larger amounts, ROS can induce 
irreversible cellular damage, which is often observed in cardiac diseases, including 
ischemia-reperfusion (Gottlieb et al., 1994), inflammation and cardiac hypertrophy 




2.6.6. Mitochondrial dysfunction in heart failure 
Due to the constant demand of energy by the cardiac muscle, defects in mitochondrial 
ATP production severely affect its function, potentially leading to cardiac failure and 
death. Decreased mitochondrial oxidative metabolism and phosphocreatine levels 
(Conway et al., 1991; Neubauer et al., 1997), genetic defects arising from nDNA and 
mtDNA mutations (Antonicka et al., 2003, Brecht et al., 2015; Andreu et al., 2000; 
Abdulhag et al., 2014) and conditions causing mitochondrial dysfunction as a 
secondary effect, such as in cases of ischemic injury (Piper et al., 1985; reviewed by 
Chen et al., 2007), have been observed in several forms of heart failure. In addition, 
IFM serve as a sink for Ca2+ from the sarcoplasm, and disturbed calcium homeostasis 
has widespread effects on mitochondrial metabolism (Otto et al., 1977, Wan et al., 
1989; reviewed by Pohjoismäki et al., 2017), as well as affecting antioxidant 
mechanisms. Thus, mitochondrial dysfunction and metabolic adaptation or 
maladaptation of the myocardium are closely connected. Alternatively, mitophagy, 
which is selective degradation of mitochondria by autophagy, has been shown to be 
essential for cardioprotection under conditions of ischemic stress (Huang et al., 
Figure 7: ROS production in the OXPHOS pathway. ROS is produced both as a consequence of normal
electron transport and due to dysfunctional OXPHOS. Electron leak from cI and cIII, which are the major
sites of ROS production in the OXPHOS pathway, leads to one-electron reduction of oxygen into ROS.
Excessive ROS production contributes to mitochondrial dysfunction causing several irreversible types 
of damage, including that to mtDNA and enzymes of the TCA cycle, further affecting the OXPHOS 
pathway and resulting in less ATP production. Severe oxidative damage can also lead to the release of
cytochrome c from the IMS to the cytosol, which in turn signals the induction of cell death. Note, ROS













































2011). These observations make mitochondrial dysfunction and homeostasic 
responses to it a complex yet critical parameter in the progression of heart failure. 
In order to better understand the impact of mitochondrial dysfunction in conditions of 
heart failure, I studied two genetically modified mouse models, which I now describe. 
 
2.7. Mcp1 mouse model 
Monocyte chemoattractant protein (MCP1) is a chemokine (chemotactic cytokine) 
that regulates the migration and infiltration of monocytes, natural killer (NK) cells and 
memory T-cell lymphocytes. MCP1 is expressed and secreted by many cells, 
including fibroblasts, inflammatory, endothelial, smooth muscle, astrocytic and 
microglial cells, in response to a proinflammatory stimuli and tissue injury (reviewed 
by Deshmane et al., 2009, Niu et al., 2009). When secreted, chemokines bind to 
specific receptors on the surface of immune cells, inducing migration towards the 
chemokine source, mediated by the chemokine concentration gradient. MCP1 was 
also shown to regulate the expression of monocyte cell surface adhesion molecules, 
induce the secretion of interleukins IL-6 and IL-1 (Jiang et al., 1992) and regulate the 
expression of NADPH oxidase family proteins following ischemia/reperfusion injury 
(Morimoto et al., 2008), as well as that of matrix metalloproteinases (MMPs), TGF-β 
and TGF-β1 (Niu et al., 2009). These observations indicate that MCP1 can function 
as a chemokine and regulate gene expression in the heart to mediate 
proinflammatory responses through interleukins, cardiac remodeling via MMPs and 
oxidative stress response via NADPH oxidase family proteins. Addition of external 
MCP1 showed significant protection against apoptosis in cardiomyocytes exposed to 
hypoxic conditions followed by reoxygenation, while untreated cardiomyocytes 
showed induced apoptosis (Morimoto et al., 2008). In a knockout mouse model for 
CCR2, the primary receptor for MCP1, experimentally induced myocardial infarction 
resulted in a decreased infiltration of macrophages and subsequent gene expression 
of MMPs and TNFα in the infarcted region, compared with control mice, and was 
beneficial for left ventricular remodeling (Kaikita et al., 2004). Serum MCP1 levels 
were found to be elevated in patients suffering from ischemic stroke and myocardial 
infarction (Arakelyan et al., 2005) and an ischemia/reperfusion experiment on rat 
kidney showed elevated MCP1 expression mediated by activation of NF-κB and 
oxidative stress (Sung et al., 2002). These studies provide a potential link between 
oxidative stress, MCP1-mediated inflammatory responses and pathogenesis in 
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ischemic conditions. MCP1 is one of the most studied chemokines and its 
involvement has been documented in several diseases, including HIV-1 
pathogenesis, atherosclerosis, cardiac ischemia, coronary artery disease, multiple 
sclerosis and some tumors (reviewed by Deshmane et al., 2009, Niu et al., 2009). 
In order to understand the underlying mechanism by which MCP1 triggers the 
progression of cardiovascular diseases involving inflammation, a mouse model was 
generated showing constitutive expression of mouse MCP1 in adult cardiomyocytes 
(Kolattukudy et al., 1998, hereafter referred to as Mcp1 mice). Mcp1 mice developed 
lethal cardiac failure. The severity of the phenotype was transgene-dose dependent: 
mice homozygous for overexpressed MCP1 suffered early lethality, at about 6 months 
of age, whereas heterozygous overexpressing mice survived to about 1 year of age. 
Echocardiographic analysis of one-year-old Mcp1 mice revealed poor cardiac 
contractility and increased left ventricular mass compared to wild-type mice 
(Kolattukudy et al., 1998). Conversely, under conditions of ischemia/reperfusion, 
Mcp1 mice showed better LV diastolic function and decreased ROS generation, 
accompanied by increased CuZn-SOD activity in the myocardium, compared to wild-
type mice (Morimoto et al., 2008). Further studies on Mcp1 mice have revealed 
mitochondrial abnormalities, including swelling and dense deposits, decreased 
creatine phosphate/ATP ratio and increased ROS or inducible nitric oxide synthase 
(iNOS; Niu et al., 2009). Administration to Mcp1 mice of cerium oxide (CeO2) 
nanoparticles, shown to exhibit antioxidant properties (reviewed by Dhall et al., 2018), 
attenuated left ventricular dysfunction, diminished monocyte/macrophage infiltration 
and myocardial oxidative stress, and decreased the expression of proinflammatory 
cytokines, ER-stress markers and heat shock proteins (HSPs; Niu et al., 2007). 
Additionally, MCP1 binding to CCR2 results in the expression of MCP1-induced 
protein (MCPIP), a zinc-finger protein that functions as a transcription factor. Chronic 
expression of MCPIP in cardiomyoblasts has been shown to induce oxidative and 
ER-stress and to activate autophagy (Younce et al., 2010), suggesting that these 
processes are causally linked (Younce et al., 2010; Kolattukudy et al., 2012). 
However, the source of oxidative stress is yet to be clearly understood. Since 
mitochondria are a major source of ROS production in the cell, mainly due to electron 
leak via respiratory complexes I and III under conditions of respiratory chain overload 
or dysfunction, mitochondrial ETC dysfunction could play a critical role in MCP1-
mediated cardiac failure. Although macrophages themselves produce ROS (Tieu et 
al., 2009), previous observations of mitochondrial structural abnormalities and 
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decreased ATP production in the heart of Mcp1 mice (Niu et al., 2009) suggested a 
potential involvement of mitochondrial-ROS production in the pathophysiology. In 
order to understand if the observed mitochondrial dysfunction is either the cause or 
the consequence of the induced oxidative stress, I expressed AOX in Mcp1 mice. 
Assuming ROS production via a defective or overloaded cytochrome pathway of the 
mitochondrial respiratory chain is a major contributor to the underlying molecular 
mechanism, AOX should be able to mitigate it and thereby reduce the symptoms. 
 
2.8. Cox10 mouse model 
COX10, also known as heme A:farnesyltransferase or Heme O synthase, is a 
nuclear-coded enzyme required for the assembly of mitochondrial cIV. It catalyzes 
the conversion of heme b to heme o in the heme biosynthetic pathway. Heme o is 
then rapidly converted by COX15 to heme a, which is essential for the function of cIV. 
Both COX10 and COX15 are embedded in the IMM, and the protein levels, in yeast, 
are in the ratio of 1:8, respectively (Wang et al., 2008). COX10 shares a high 
sequence similarity among yeast, human and bacteria, with the exception of an 
amino-terminal domain of approximately 150 residues that is absent in bacteria 
(Nobrega et al., 1990, Glerum et al., 1994). The human COX10 gene is approximately 
135 kb in length, comprises 7 exons and is ubiquitously expressed, with highest 
expression levels in the heart, skeletal muscle and testes (Murakami et al., 1997). 
Mutations in COX10 have been reported in several patients with clinical 
manifestations of leukodystrophy and tubulopathy, fatal infantile hypertrophic 
cardiomyopathy, anemia, sensineural deafness and Leigh-like syndrome (Valnot et 
al., 2000, Antonicka et al., 2003, Coenen et al., 2004). The patients exhibited rapid 
progression of clinical symptoms, isolated COX deficiency and decreased levels of 
heme A. Over-expression of COX10 using retroviral COX10 cDNA in cultured patient 
fibroblasts normalized COX activity (Antonicka et al., 2003, Coenen et al., 2004) by 
replenishing heme A levels (Antonicka et al., 2003), indicating that COX10 activity 
could be a rate-limiting step in the formation of heme a, and thus of the assembly of 
COX and its activity. 
To study the molecular mechanisms involving COX deficiencies, a conditional KO 
mouse model for COX10 was generated by flanking exon 6 of Cox10 with loxP 
recognition sites (Diaz et al., 2005). Cox10-floxed mice were reported to be 
indistinguishable from wild-type mice. Muscle-specific Cox10 KO achieved by 
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crossing the floxed mice with mice expressing a muscle-specific Cre driver (mlc1f-
Cre) showed a late-onset phenotype of muscle weakness and inactivity leading to 
death by 7 months of age. Loss of COX holoenzyme and severe deficiency of its 
activity were accompanied by the accumulation of enlarged mitochondria and loss of 
muscle tissue (Diaz et al., 2005). 
Liver-specific KO of Cox10, achieved by crossing Cox10 floxed mice with mice 
expressing Cre under the control of the rat albumin reporter, exhibited a liver 
phenotype, with severity correlating in a dose-dependent manner with Cre expression 
levels (Diaz et al., 2009). Phenotypic abnormalities included loss of total body weight, 
increased lipid accumulation, severe decrease in COX activity, prominent 
mitochondrial proliferation and a mild decrease in ATP levels in younger mice. 
Interestingly, loss of cIV activity was complemented by an increase in activity of other 
respiratory chain complexes. However, as the steady-state levels of Cre decreased 
with age, COX activity and the number of COX-positive cells almost normalized to the 
levels of control mice (Diaz et al., 2009). 
These studies highlight the potential use of Cox10 floxed mice to study COX 
deficiency in specific tissues, thus mimicking diseases with both tissue-specific and 
multi-organ manifestation. I used this mouse model to study COX deficiency in heart 
tissue, as described in section 4.4. 
Aiming to reveal the role of respiratory chain defects leading to mitochondrial 
dysfunction in the above models, I combined them with mice expressing AOX, as 
described in the next section. Before describing the AOX-expressing mouse models, 
I provide background information relating to the expression of AOX from Ciona 
intestinalis in human cells and Drosophila. 
 
2.9. AOX models 
 
a. Human cell-culture models 
Xenotopic expression of AOX from Ciona intestinalis, in cultured human embryonic 
kidney (HEK) cells showed no detrimental effect under normal conditions (Hakkaart 
et al., 2006), providing initial evidence for the safe expression of AOX in a mammalian 
context. When expressed, AOX localized to mitochondria and conferred enzymatic 
activity only in the presence of cyanide or antimycin A, which affects the standard 
34 
 
ETC by blocking cIII or cIV activity, respectively. Additionally, AOX also conferred 
protection against antimycin-induced superoxide production (Hakkaart et al., 2006). 
Similarly, AOX expression complemented defects in respiration, in cell growth on low-
glucose media, as well as antimycin-induced cell death and superoxide production, 
in human cells depleted of either COX10 or COX15 (Dassa et al., 2009).  
 
b. Drosophila models 
Observations of such beneficial effects of Ciona AOX in human cells inspired the 
generation of transgenic Drosophila models expressing Ciona AOX (Fernandez-
Ayala et al., 2009, Kemppainen et al., 2014). Drosophila ubiquitously expressing AOX 
were viable and fertile. However, they exhibited a minor delay in development and 
minor weight loss in younger flies; otherwise, the flies did not show any major 
phenotypic difference from wild-type animals. Like in the case of transgenic HEK 
cells, AOX flies exhibited resistance to cyanide and antimycin A in vivo, as well as 
cyanide resistance when respiration was analyzed in isolated mitochondria. 
Additionally, AOX expression in flies also prevented lethality caused by partial 
knockdown of cytochrome oxidase, and complemented the detrimental phenotype in 
a fly model of Parkinson’s disease, dj-1β mutant (Fernandez-Ayala et al., 2009). 
 
c. Mouse models 
Following the successful expression of AOX in human cells and Drosophila, three 
different lines of mice expressing AOX were generated. The first mouse model 
(hereafter referred to as MitAOX mice) harbored the coding sequence of Ciona AOX, 
codon-optimized for enhanced expression, introduced into the germline by lentiviral 
transduction (El-Khoury et al., 2013). MitAOX mice were viable, exhibited no 
observable phenotypic differences from wild-type mice and showed widespread 
expression of AOX protein, which localized to mitochondria. Additionally, stable AOX 
expression did not affect the expression levels of endogenous respiratory complex 
subunits or the amount of ETC supercomplexes. However, the use of lentiviral 
transduction to create the model resulted in multiple integrations of the AOX 
transgene, such that ubiquitous, high-level expression could not be stably 
transmitted. This made the MitAOX model unsuitable for long-term maintenance or 
for combination with disease models of disease.  
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In order to create a genetically tractable AOX mouse line, the second mouse model 
(AOXRosa26) was generated by site-directed integration of Ciona AOX into the mouse 
Rosa26 locus (I). In this model, the AOX transgene was inserted downstream of 
synthetic CAG promoter (figure 8A), so as to achieve strong and ubiquitous 
expression. These mice were the starting point for the study, and their detailed 
phenotypic analysis is described below, in section 4.1, and published papers (I) and 
(II). AOXRosa26 mice were subsequently demonstrated to rescue the lethality and 
confer protection against detrimental phenotypes when combined with a mouse 
model for GRACILE syndrome, Bcs1l mutant mice (Rajendran et al., 2019), or in a 
mouse model for sepsis, induced by administration of LPS (Mills et al., 2016). 
Conversely, when combined with a mouse model for skeletal muscle-specific COX 
deficiency, via muscle-specific Cox15 KO, AOX expression was found to exacerbate 
the phenotype. It was inferred to blunt superoxide production, thereby affecting ROS-
mediated response pathways, which were necessary for cellular regeneration (Dogan 
et al., 2018). 
Aiming to study the effect of tissue-specific AOX expression, and its ability to modify 
the phenotype of disease models that exhibit tissue-specific metabolic defects, a 
mouse model conditionally expressing AOX (SNAP-AOXRosa26) was also generated 
(III). The characterization of this model also forms part of my thesis, as described in 
(III). The difference between ubiquitous and conditional AOX models is the addition, 
upstream of AOX, of the coding sequence of the SNAP-tag (derived from human O6-
alkylguanine-DNA-alkyltransferase (AGT), Keppler et al., 2004), followed by an SV40 
pA sequence for 3’ RNA processing (figure 8). The additional sequence was 
surrounded by loxP sites to enable Cre-mediated excision. In this system, the CAG 
promoter naturally drives the expression of SNAP unless the SNAP cassette is 
removed by Cre-mediated recombination between the loxP sites, thus enabling the 
CAG promoter to drive the expression of AOX. Further details on this mouse model 




Figure 8: Schematic diagram of the AOX expression constructs of the AOXRosa26 and SNAP-AOXRosa26
mouse model. A) Single copy of Ciona AOX coding sequence integrated into the Rosa26 locus of mouse
chromosome. AOX expression is driven by synthetic CAG promoter, and transcription termination by 
beta globin poly A signal. B) Expression construct of SNAP-AOXRosa26 mice has additional elements
compared to the construct of AOXRosa26 mice between the CAG promoter and the AOX transgene, in 
the following order: loxP site, SNAP coding sequence, SV40 poly A sequence and loxP site. Through
Cre-mediated recombination, the loxP flanked STOP cassette is excised leaving one loxP site, and thus
allowing for AOX expression. In the absence of Cre-mediated recombination, only SNAP is expressed.
Figure reprinted from (III) under Creative Commons Attribution 4.0 International License (CC by 4.0). 
cre-mediated 
recombination
Rosa26 pCAG SNAPloxP loxP AOX -G intron/pA Rosa26SV40 pA
Rosa26 pCAG loxP -G intron/pA Rosa26AOX






The general aim of this thesis work was to study the consequences of mitochondrial 
respiratory chain defects in mouse cardiomyopathy models, using AOX as a tool. 
The more specific aims of this work were: 
1. To profile the effects of expressing AOX in the mouse under non-stressed 
conditions and dietary manipulation manipulation, as essential background 
information for the cardiomyopathy study. 
2. To test the effects of AOX expression in a mouse model of inflammatory 
cardiomyopathy, proposed to be mediated by oxidative stress.- 
3. To investigate whether AOX can mitigate the effects of severe mitochondrial 




4. Materials and Methods 
4.1. Animal handling and ethical considerations 
Wild-type mice (C57BL/6JOlaHsd) were purchased from Envigo. All transgenic mice 
used in (I), (II) and (III) were backcrossed into the C57BL6/JOlaHsd background for 
over 8 or more generations before the start of each experiment. Tissue-specific AOX 
expression was achieved by crossing SNAP-Aox mice with mice expressing ACTB-
Cre (The Jackson Laboratory, Stock No: 019099), for ubiquitous expression, or with 
mice expressing Myh6-Cre (The Jackson Laboratory, Stock No: 011038), for adult 
cardiomyocyte-specific expression. All animals were treated according to regulations 
detailed by the Finnish animal welfare board (ELLA), and all the experiments 
performed were approved and run according to the ethical permits 
ESAVI/8766/04.10.07/2015 and ESAVI/2954/04.10.07/2015. Mice were housed in a 
humidity and temperature-regulated animal facility with food and water provided ad 
libitum and a 12-hour light/dark cycle. After completion of the experiments, mice were 
euthanized either by cervical dislocation or, in some cases, exposure to CO2 followed 




Cardiac ejection fraction and left ventricular mass were determined by 
echocardiography (Vevo 2100 system, FujiFilm VisualSonics Inc.). Mice were 
anesthetized using 4% isoflurane and were placed on a warm platform, maintained 
at 37 °C during the entire measurement. The obtained images were used to measure 
ventricular parameters using Vevo Lab software.  
 
4.3. Treadmill 
Treadmill (Exer- 6M Treadmill, Columbus Instruments) running was performed to 
measure mouse exercise endurance. Mice were trained on the treadmill for 3 days 
before the experiment. On the experiment day, mice were placed on the treadmill and 
the instrument was set to gradually reach a speed of 6.5 m/min before the start of 
measurement. The speed was then raised in steps of 0.5 m/min every 3 min. Mice 
were removed from the treadmill chamber immediately following a stay of more than 
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5 s on the electrified motivation grid (0.5 mA current), which was considered as the 
end point of each test. Either run-time (I) or run distance (II) was evaluated as an 
indicator of mouse performance. 
 
4.4. Grip Strength analysis 
Grip strength of the mice was measured using the BIO-GS3 apparatus (Bioseb). Mice 
were placed on the metallic grid platform until all four limbs were completely engaged 
on the grid. Then mice were pulled gently, to measure the force generated. Every 
measurement was repeated three times and the mean value was normalized to body 
weight (g/g) for each animal tested. All animals were trained for three successive days 
before the actual experiment. 
 
4.5. DEXA imaging 
DEXA imaging (GE LUNAR PIXImus2 imager) was used to measure mouse body 
composition. Before imaging, animals were anesthetized with a 1:1 mixture of 
pentobarbital (Orion Pharma, 100 mg/kg of body weight) and lidocaine (Orion 
Pharma, 16 mg/kg of body weight). Once anesthetized, mice were placed in the 
instrument for imaging, taking approximately 15 min per measurement.  
  
4.6. Blood metabolite measurements 
Blood droplets were collected from the tail vein by making a small incision. Glucose, 
lactate, and ketone body concentrations were measured using Freestyle Precision 
(Abbot Laboratories, USA), Lactate Pro (Arkay, Kyoto, Japan), and Freestyle 
Precision metering instruments, respectively, according to manufacturer’s 
instructions.  
 
4.7. Diet manipulation 
Male littermates were randomized into different diet groups and were either caged in 
littermate groups (2–5 per cage) or individually, which was done for a small group, as 
described in II. Special diets, sterilized by irradiation, were introduced 8 weeks after 
birth. This delay ensured that the mice were already accustomed to solid food. They 
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were maintained on the relevant diet for 40 weeks. Diets used were standard chow 
(Teklad 2918, Teklad Global 18% Protein Rodent Diet), high fat (HF-60; Teklad 
Custom Diet TD.06414) and ketogenic (Teklad Custom Diet TD.96355). Animals 
were weighed at regular intervals, twice weekly, and the change in body weight was 
recorded. 
 
4.8. DNA extraction and genotyping 
Total DNA was extracted from ear punches or tail cuts using either standard 
laboratory methods as described in (I) or with a commercially available extraction kit, 
ExtractaTM DNA prep for PCR (QuantaBio), in (II) and (III). PCR genotyping was 
carried out to verify the genotype of all mice at the manipulated loci, using primers 
listed in Table 2. PCR reactions contained 4 pmol of each primer, and either DMSO 
at 2%, 0.2 μl DyNazyme II (Thermo Fisher Scientific) in (I) or Accustart II PCR 
SuperMix (QuantaBio) in (II) and (III). The cycle parameters were as follows: Initial 
denaturation at 95 °C for 5 min, then 39 cycles of denaturation at 95 °C for 20 s, 
respective annealing temperature (Table 2) for 30 s and extension at 72 °C for 60 s, 
with a final extension step at 72 °C for 10 min. The PCR products were verified using 
agarose gel electrophoresis. 
 
4.9. RNA extraction, Northern blotting and RT-qPCR 
RNA was prepared from frozen mouse tissues by bead-homogenization (Precellys 
lysing kit, Bertin Instruments) in 700 μl (> 10 volumes) of Trizol reagent (Sigma). After 
incubation for 5 min at room temperature, 0.2 volume of chloroform was added 
followed by centrifugation at 12,000 gmax for 15 min at 4 °C. The upper (aqueous) 
phase, containing RNA, was transferred to a fresh tube and an equal volume of 
isopropanol was added, followed by centrifugation at maximum speed, 21,000 gmax, 
for 10 min at 4 °C. Isopropanol was then decanted and the RNA pellet was washed 
in 70% ethanol, with a further centrifugation at 21,000 gmax for 5 min at 4 °C. After 
decanting the ethanol, RNA pellets were air-dried followed by resuspension in 20 μl 
RNase-free water and quantification using NanoDrop spectrophotometry. 
For Northern blotting, resuspended RNA pellets were fractionated on formaldehyde 
(20%)-agarose gels followed by blotting to Hybond N+ membrane (GE Healthcare). 
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The blot was hybridized with end-labelled (32P labelling) DNA probes, as described in 
(I). 
For RT-qPCR, 1 μg of RNA was treated with DNase enzyme and was reverse 
transcribed using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR 
(ThermoFisher Scientific). The processed samples were then diluted to 1:10 with 
nuclease-free water and 5 μl of the dilution was used for RT-qPCR reactions using 
the SensiFAST SYBR® No-ROX Kit (Bioline) and primers listed in (III).   
 
4.10. Protein extraction and Western blotting 
Small pieces of fresh or frozen tissue were placed in 500 μl of lysis buffer (50 mM 
Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 7.4,) containing a 
dissolved protease inhibitor cocktail tablet (Pierce), in a 5 ml tube on ice. 
Homogenization was done using a POLYTRON® PT 1200 E Manual Disperser 
(Ecoline). Homogenates were transferred to fresh 2 ml tubes and were incubated on 
ice for 30 min followed by centrifugation at 14,000 gmax for 5 min at 4 °C. Supernatants 
were transferred to a fresh tube and protein concentration was measured using the 
Bradford reagent (Bio-Rad). After quantification, samples were diluted into SDS-
PAGE sample buffer for electrophoresis on SDS-12% polyacrylamide gels (10 μg of 
protein per lane), followed by transfer to PROTRAN nitrocellulose membranes 
(PerkinElmer) by semi-dry transfer (I) or PVDF membranes using Trans-Blot® 
TurboTM PVDF Transfer pack (Bio-Rad; III). A complete list of antibodies used are 
presented in Table 3. 
 
4.11. Mitochondrial isolation and respirometry 
Organs harvested from mice were collected in 15 ml Falcon tubes containing ice-cold 
PBS. Soft tissues (brain, lung and liver) were fine-chopped (to ca. 1 mm3) in ice-cold 
PBS and hand-homogenized in 3 ml extraction buffer (225 mM sucrose, 75 mM D-
mannitol, 10 mM Tris/HCl, 1 mM EGTA, 1 mg/ml bovine serum albumin (BSA), pH 
7.4) using a glass-teflon homogenizer. Hard tissues (heart, skeletal muscle and 
kidney), chopped to a similar size, were treated with 3 ml (approx. 10 volumes) ice-
cold trypsin-EDTA (500 μg/ml trypsin (Difco), 0.5 mM EDTA, 10 μg/ml phenol red, pH 
7.4) for 10 min followed by blocking with 300 μl fetal bovine serum (Gibco/Life 
Technologies). The treated tissue pieces were then homogenized using a glass-teflon 
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homogenizer. Homogenates were transferred to fresh 15 ml tubes and centrifuged at 
1,300 gmax for 5 min at 4 °C. Supernatants were collected and re-centrifuged at 17,000 
gmax for 15 min at 4 °C. The obtained pellet was resuspended, according to its size, 
in 75-250 μl of ice-cold MiR05 buffer (0.5 mM EGTA, 3 mM MgCl2, 60 mM lactobionic 
acid (Aldrich, buffered to pH 7.0 with 5 M KOH), 20 mM taurine (Sigma), 10 mM 
KH2PO4, 20 mM HEPES/KOH, 110 mM sucrose and 1 g/l fatty-acid free BSA (Sigma), 
pH 7.2 at room temperature) and stored on ice until respirometry. Mitochondrial 
protein content was measured using the Bradford reagent (Bio-Rad).  
Respirometry was performed on freshly resuspended mitochondria using an O2K 
oxygraph (Oroboros). 2 ml of MiR05 buffer was added to the 2 ml chamber, to which 
50 or 100 μg of mitochondria was added, according to the tissue. Substrates and 
inhibitors were added in the following order: (i) 5 mM sodium pyruvate + 5 mM sodium 
glutamate + 5 mM sodium malate, (ii) 4 mM ADP, (iii) 150 nM rotenone (Sigma), (iv) 
17 mM sodium succinate, (v) 22.5 ng/ml antimycin A (Sigma), (vi) 200 μM n-propyl 
gallate (nPG, Sigma) (vii) 0.5 mM N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD, 
Sigma) + 2 mM sodium L-ascorbate (viii) 100 mM NaN3 or 1 mM KCN. The flux values 
(pmol/s*ml) obtained from the trace were normalized to the amount of mitochondrial 
protein and final values of flux (pmol/s*μg) were used for evaluations.  
 
4.12. Collaborative experiments 
Detailed protocols for all collaborative experiments are provided in the respective 
publications. For gut microbiome analysis, animal droppings were collected from 48-
week old mice and were stored at 20 °C until further processing. For electron 
microscopy, mice were sacrificed by cervical dislocation and a small piece of left 
ventricle was collected and stored in a buffer containing 1.5% glutaraldehyde, 1.5% 
formaldehyde, 0.15 M HEPES/KOH, pH adjusted to 7.4, until further processing. For 
metabolomics (I), food was withdrawn 4-6 hours before sacrifice, followed by 
collection of a small piece of left ventricle. Samples were kept frozen until further 
processing. For metabolomic flux analysis (III), food was withdrawn 4-6 hours prior to 
the experiment. Mice were anesthetized with 4% isoflurane and were injected with 
either U-13C6 labeled (CLM-1396, Larodan) or 12C6 (492167, Sigma-Aldrich) 
glucose solution (2 g/kg bodyweight). 15 min after the injection, mice were sacrificed 
by cervical dislocation and a small piece of left ventricle was collected, snap frozen 
in liquid nitrogen and stored at -80 °C until further processing. In both experiments, 
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water was provided ad libitum. For analysis of CoQ, mice were sacrificed by cervical 




All data are reported as mean±SD. Data groups were compared by one-way ANOVA 
with post hoc Tukey HSD (multiple comparisons) test or, where two factors were 
considered, by two-way ANOVA, followed by post hoc Tukey HSD (multiple 
comparisons) test where interaction was detected or where more than two levels were 
considered for a given significant factor. 
In (II), all data, except gut microbiome analysis, were analyzed using GraphPad Prism 
software. 
In (III), survival curves were compared by the log-rank (Mantel-Cox) and Gehan-
Brewslow-Wilcoxon tests, all using GraphPad Prism software. Significant differences 
from expectation, of progeny numbers of different output genotypes from crosses, 
was assessed by chi-squared test with Yates’ correction for continuity, implemented 
using online tool (http://www.quantpsy.org/chisq/chisq.htm).  
Statistical analyses presented in Supplementary Tables give exact p-values, which 
are generally quoted in figures and legends using a conventional *, **, *** 




Table 2: List of primers used 






Aox_F GCGATGCAAGATGGAGGGTA 317 56 
Genotyping 
by PCR 
Aox_R TGAATCCAACCGTGGTCTCG  
Rosa26_F GACCTCCATCGCGCACTCCG 520 56 
Rosa26_R CTCCGAGGCGGATCACAAGC 
Cag_F GGGCAACGTGCTGGTTATTG 400 63 
SNAP_R AAGCTCTCCTGCTGGAACAC 








ACTB-Cre_F GCGGTCTGGCAGTAAAAACTATC 100 64 
ACTB-Cre_R GTGAAACAGCATTGCTGTCACTT 
Mcp1_F TTCTCTGCCCAGCTGCCC 500 58 
Mcp1_R CCTTCCTTTTTATGCTCC 
Cox10_F ACCCATTAGAAACTGCTGATGGCT Cox10 wt 
- 700; 
Cox10 
flox - 840 
61 
Cox10_R CACTGACGCAGCGCCAGCATCTT 
Myh6_F CTACAAGCGCCAGGCTGAG 188 
60 RT-qPCR 
Myh6_R GGAGAGGTTATTCCTCGTCGT 
Myh7_F GCTGTTTCCTTACTTGCTACCC 198 
Myh7_R GCCTCTCCTTCTCAGACTTCC 
GATA4_F TTTTCTGGGAAACTGGAGCTGG 159 
GATA4_R ATCACCCACCGGCTAAAGAAG 
Egln3_F AATGGTGATGGCCGCTGTAT 173 
Egln3_R TCATGTGGATTCCTGCGGTC 
Gpx3_F CATCCTGCCTTCTGTCCCTG 126 
Gpx3_R CGATGGTGAGGGCTCCATAC 
SOD2_F CGTGAACAATCTCAACGCCA 172 
SOD2_R TCCTTTGGGTTCTCCACCAC 
Mtor_F CGCTACTGTGTCTTGGCATC 237 
Mtor_R CTTGATTCTCCCAATGCCGC 
IL10_F AGGCGCTGTCATCGATTT  91 
IL10_R CACCTTGGTCTTGGAGCTTAT  
Mcp1_F CTGCTGTTCACAGTTGCCG 218 
Mcp1_R CATTCCTTCTTGGGGTCAGC 
FGF21_F CTGGGGGTCTACCAAGCATA 220 
FGF21_R CAC CCA GGA TTT GAA TGA CC 
RPS18_F GTTCCAGCACATTTTGCGAGT 136 
RPS18_R GGTGAGGTCGATGTCTGCTT 




Table 3: List of antibodies used 
Antibody Company Catalog 
number 
Species Dilution Detected size 
(KDa) 
Porin Abcam  ab15895 rabbit 1:1,000 37 
OXPHOS 
cocktail 
Abcam  ab110413 mouse 1:250 NDUFB8  - 20 
     
SDHB - 25 
     
UQCRC2 - 48 
     
MTCO1 - 40 
     
ATP5A - 55 
NDUFS3 Mitosciences ab14711 mouse 1:4,000 24 
HSP60 Abcam  ab46798 rabbit 1:20,000 60 
GAPDH Cell Signalling #2118 rabbit 1:1,000 37 
LC3b Novus NB600-1384 rabbit 1:1,000 LC3-I - 10 
     


























5.1 Impact of AOX expression in mice under non-stressed conditions 
I studied the consequences of AOX expression in mammals using two different 
mouse lines, one designed to express AOX ubiquitously (AOXRosa26), the other 
containing a tissue-specific, conditionally activatable AOX transgene (SNAP-
AOXRosa26). These mouse models were generated (Dr. M. Szibor) by integrating the 
Ciona intestinalis AOX coding sequence into the Rosa26 locus, as described in 
Chapter 2.  
A broad initial assessment of general traits including size, color and general mobility 
of mice in cages showed no observable differences between wild-type and transgenic 
mice. Note, these were mere qualitative assessments and no quantitative 
measurements were made for the above-mentioned parameters. The mice were 
originally generated in the C57Bl6/J background and were backcrossed to the 
C57Bl6/JOlaHsd background in Helsinki due to their ready availability and wide use 
among local research groups. The major difference between these two strains is a 
deletion in the alpha synuclein (Snca) and multimerin-1 (Mmrn1) genes in 
C57Bl6/JOlaHsd mice. C57Bl6/JOlaHsd mice were reported to show some minor 
phenotypic differences including impaired platelet adhesion, impaired thrombus 
formation (Reheman et al., 2010) and decreased motor impulsivity (Pena-Oliver et 
al., 2014) when compared to C57Bl6/J mice. Except for these differences 
C57Bl6/JOlaHsd mice were not reported to show any obvious phenotype and are 
generally used as wild-type control (Specht & Schoepfer, 2004). However, in a recent 
study, C57Bl6/JOlaHsd mice were reported to exhibit a significant decrease in 
trabecular bone mass (Liron et. al., 2018). In all experiments reported in this thesis, 
the mice were backcrossed over 8 or more generations before crosses for 
phenotyping of the model or its progeny were made. After backcrossing, the above-
mentioned basic traits of the mice continued not to differ qualitatively. 
In order to evaluate these mouse models in detail, I first profiled the expression of 
AOX in different tissues. In the case of the conditionally activatable SNAP-AOXRosa26 
line this was done both before and after Cre-mediated activation. Next, I assessed 
the physical performance of the mice in comparison with non-transgenic littermates. 
I then evaluated the impact of AOX expression on relevant molecular parameters and 





5.1.1. Expression profiling in AOX transgenic mice 
Ideally, to use AOX as both a research tool and as a model for therapy, expression 
should be strong and ubiquitous. Therefore, the CAG promoter was initially selected 
to drive the expression of AOX. In order to test the prediction of ubiquitous expression, 
I analyzed the expression of the AOX transgene at the RNA and protein level, in 
different tissues of AOX mice. 
a) AOXRosa26 mice: RNA expression analysis using Northern blotting was carried 
out on heart, lung, liver, brain, kidney, spleen, testis and skeletal muscle 
tissues from both wild-type and AOXRosa26 mice. AOX mRNA, 1.1 kb, was 
detected in all the tissues tested from AOX-expressing mice but not in wild-
type mice, as expected. The expression levels of AOX, however, differed 
between tissues, with the highest levels observed in heart and skeletal muscle 
and the lowest in the brain (figure 9A). Protein expression analysis performed 
by western blotting using total protein extracts from heart, thigh muscle, 
masseter muscle, pancreas, lung, liver, kidney, spleen, cerebrum cerebellum, 
salivary gland and testis showed AOX expression in all the tissues (figure 9B). 
The pattern of relative protein expression in different tissues was similar to 
that of the mRNA, with the highest expression in heart and muscle and the 
lowest in brain. 
Figure 9: Expression analysis of AOX in mice. (A) Northern blotting showing RNA expression and (B) 
Western blotting showing protein expression from different tissues from 1-year-old male mice. He –
heart, Lu – lung, Li – liver, Br – brain, Ki – kidney, Sp – spleen, Te – testes, Sk – skeletal muscle, Tm –
thigh muscle, Mm – masseter muscle, Pa – pancreas, Ce – cerebrum, Cb – cerebellum, Sg – salivary
gland. cI – cV shown in (B) were stained with OXPHOS cocktail antibody. Genotype and respective
band sizes are as shown in the figure. Image reprinted from (I) under CC by 4.0 license. 
48 
 
In addition, based on experiments in brain tissue of one-month old mice 
(conducted by Dr. K. Holmström and Y. Zhuang), mice homozygous for AOX 
showed approximately two-fold higher expression of the protein compared to 
the heterozygous mice (figure S2D of paper (I)). The reason for different 
expression levels in different tissues is unknown but given that AOX is a 
mitochondrial protein, variation in the amount of mitochondria or respiratory 
capacity could be possible reasons.  However, this does not explain the 
reason for very low AOX expression levels in the brain of AOX mice. This 
issue is discussed in depth in the next chapter. 
 
b) SNAP-AOXRosa26 mice: As described in Chapter 2, without recombination 
catalyzed by Cre, AOX expression cannot be activated in these mice. In order 
to verify that AOX expression can be activated in this manner, I analyzed 
protein expression using western blotting on different tissues from SNAP-
AOXRosa26 mice with and without Cre recombination. Without Cre 
recombination, all the tissues tested were expressing SNAP but not AOX 
protein. To check the activation of AOX expression, I crossed SNAP-
AOXRosa26 mice with mice expressing Cre ubiquitously, driven by the beta-
Actin (ACTB) promoter, and, in a separate experiment, with mice expressing 
Cre only in adult cardiomyocytes, driven by the alpha-myosin heavy chain 
(Myh6) promoter. In both cases, I was able to activate AOX expression as 
predicted (figure 10). In general, expression of SNAP protein was not 
observed in tissues where AOX expression was activated using ACTB 
promoter; this is due to the removal of the SNAP sequence resulting from by 
Cre-mediated recombination. However, in the heart tissue from the progeny 
of SNAP-AOXRosa26 combined with mice expressing Cre under the Myh6 
promoter, residual SNAP expression was observed, which could be from the 





5.1.2. Protein localization and association 
In plants and other species where AOX is naturally expressed, it is present in the 
IMM. To verify that this was also the case for Ciona AOX expressed in mice, I 
separated membrane-bound proteins from soluble cytosolic proteins, from the liver 
tissue of AOXRosa26 mice, using sodium carbonate extraction, and then performed 
western blotting to detect the protein (figure S2E of (I)). As expected, AOX protein 
was found in the membrane but not in the soluble fraction, validated by of its 
colocalization with subunit I of complex IV (MTCO1), indicating that AOX protein is 
membrane-associated when expressed in the mouse.  
To test whether AOX protein is associated with other protein or protein complexes 
when expressed in mammals, Dr. I. Wittig performed Blue native PAGE on tissue 
lysates from heart, liver, lung, kidney, spleen, muscle testis and brain from AOXRosa26 
mice. In all the tissues tested AOX migrated predominantly as dimers and other 
multimers (figure S2F of paper (I)). Analysis of the heart mitochondria, also performed 
by Dr. I. Wittig, using Blue native PAGE confirmed that AOX was not associated with 
any endogenous respiratory chain complexes or supercomplexes (figure S2G of 
paper (I)).  
 
Figure 10: Tissue specific activation of AOX expression achieved by combining SNAP-AOXRosa26 mice
with two different Cre expressing mouse lines; ubiquitously expressing Cre under beta actin promoter
(ACTB-Cre – top lane) and cardiomyocyte specific expression under Myh6 promoter (Myh6-Cre –
bottom lane). Genotype and band sizes are as indicated. H – heart, Lu – lung, Li – liver, B – brain, K –
kidney, S – spleen, P – pancreas, Mt – thigh muscle, Mm – masseter muscle, E – eye, T – testes. Image
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5.1.3. Enzymatic activity of AOX 
The enzymatic activity of expressed AOX was verified in different tissues using 
mitochondrial respirometry. External substrates and inhibitors were supplied to 
isolated mitochondria in the presence of ADP, i.e. the conditions for state-3 or coupled 
respiration, to measure oxygen consumption driven by different respiratory chain 
complexes as well as via AOX. In order to make a broad assessment of the 
respiratory capacity or enzymatic activity of AOX in mice, I studied mitochondrial 
respiration in heart, lung, liver, brain, kidney and skeletal muscle. In all the tissues 
tested, AOX expression did not modify the activity of any of the endogenous 
respiratory-chain complexes (figure 11A). However, with the exception of brain 
mitochondria, where AOX expression was much lower than in other tissues (figure 9), 
the presence of the AOX transgene overcame the respiratory blockade resulting from 
the presence of antimycin A, an inhibitor of cIII, and maintained mitochondrial 
respiration until AOX itself was inhibited with n-propyl-gallate, a known inhibitor of 
AOX (Moller et al., 1988). Analysis from biological triplicates of samples from male 
AOXRosa26 mice indicated AOX was able to maintain a respiratory capacity of up to 90 
% of the uninhibited cII-mediated value in muscle (including heart), and about 50 – 
70 % in other tissues tested, apart from brain (figure 11A). This antimycin-resistant 
respiration was consistent between biological replicates with no major variation, 
indicating that AOX enzymatic activity does not vary between individual mice. 
Figure 11: AOX is enzymatically functional and does not affect normal physiology of mice. (A) Enzymatic
activity of AOX, measured by respirometry analysis on isolated mitochondria from different tissues as 
indicated. Oxygen consumption rate represented in pmol s-1 g-1. 1 (Mal) – rotenone-sensitive oxidation
of malate in the presence of glutamate, pyruvate and ADP; 2 (Succ) – antimycin A- plus n-propyl gallate-
sensitive succinate oxidation; 3 (AOX) – rate of n-propyl gallate-sensitive, antimycin A-insensitive
succinate oxidation; 4 (TMPD) – rate of ascorbate-reduced TMPD oxidation. (B) Mouse muscle strength
measured using grip strength analysis, and endurance measured by treadmill experiment. (C) Cardiac
ejection fraction measured either by MRI, by Dr. A. Wietelmann or echocardiography, by me. Age, sex
and genotype of mice as indicated in the figure. Figure reprinted from (I) under CC by 4.0 license. 
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Based on these results, the expression of AOX in mice was as expected, including 
its enzymatic activity that was measured by respirometry. This led me to assess the 
impact of AOX expression on biochemical and physiological parameters of the mice. 
 
5.1.4. Effect of AOX expression on mice 
Functionally active AOX contributing to mitochondrial respiration can compete with 
mitochondrial cIII and transfer electrons from the quinone (Q) pool. Since this electron 
transfer is non-proton motive, it can affect net ATP production. Although AOX is 
expected to become functionally active only under conditions where mitochondrial cIII 
and/or IV is dysfunctional, even a partial activation of AOX might nevertheless cause 
it to compete with cIII.  This will eventually result in a decline in mitochondrial ATP 
production, and thus affecting the function of many organs, especially those that are 
highly dependent on mitochondrial ATP synthesis like the heart. To test if transgenic 
AOX expression induces such malfunction, a broad phenotyping of AOXRosa26 mice 
was carried out under non-stressed conditions, to assess both physiological and 
behavioral parameters. 
Basic morphological and physiological assessment, including measurements of body 
weight for both sexes (figure 4 of paper (I)), showed no difference between AOXRosa26 
mice and their wild-type littermates. This led me to assess more complex 
physiological parameters in mice, as described below. 
 
A. Physical performance 
To assess the physical performance of the AOXRosa26 mice, I measured their 
endurance and muscle strength by treadmill and grip-strength analysis, 
respectively, at two different time points, 12 and 52 weeks of age, using wild-
type littermates as controls. At both ages, AOXRosa26 mice performed similarly 
to the controls (figure 11B). Both these analyses were also performed in an 
independent study, which was done in collaboration with the German Mouse 
Clinic (GMC) as described in section 4.1.5. The latter study, on both sexes, 





B. Cardiac function 
Cardiac function of AOXRosa26 mice was analyzed by MRI (Dr. A. Wietelmann) 
at age 10 weeks on males, and by echocardiographic imaging, done by me, 
at ages 59 and 65 weeks on both sexes. Both experiments showed that the 
cardiac ejection fraction of transgenic mice was indistinguishable from that of 
their wild-type littermates (figure 11C).  
I also performed echocardiographic imaging on SNAP-AOXRosa26 mice with 
and without transgene activation via adult cardiomyocyte-specific Cre, to test 
whether cardiac function was affected by AOX expression in these mice. I 
performed the analysis on 5 or more male mice per group at ages 12 and 16 
weeks. The results confirmed no difference in cardiac performance of SNAP-
AOXRosa26 and 'Cardio AOX' mice (mice expressing AOX only in the adult 
cardiomyocytes as shown in figure 2C of paper (III)) compared to control mice 
which, in this case, were wild-type mice, mice expressing only Cre in the adult 
cardiomyocytes, and AOXRosa26 mice. 
 
C. Molecular parameters 
If AOX is functionally active, even at a low level, it could partially replace the 
activity of mitochondrial complexes III and IV, potentially affecting their 
expression levels as a secondary effect. To test this, I analyzed the protein 
expression levels of endogenous mitochondrial respiratory chain subunits 
using western blotting. In order to perform a broad analysis and also due to 
the ubiquitous AOX expression, I prepared total protein lysates from heart, 
lung, liver, cerebrum, cerebellum, kidney, spleen, thigh muscle, masseter 
muscle and testis of 54-week old male AOXRosa26 mice for the westerns and 
probed the blot with an OXPHOS antibody cocktail. The expression levels of 
subunits representing all 5 OXPHOS complexes did not differ between 
AOXRosa26 mice and wild-type littermates (figure 9B). Since there were no 
obvious differences, I did not quantify the intensity of the bands in this 
experiment. 
To test if cardiac-specific expression of AOX affected the expression of 
endogenous mitochondrial respiratory complexes, I performed a similar 
analysis, but only on the heart tissue of Cardio AOX mice at ages 12 and 16 
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weeks old, with appropriate controls as mentioned in section 4.3.2. As 
expected, expression of AOX did not affect that of representative subunits of 
the endogenous mitochondrial OXPHOS complex (figure 5C and S3A of paper 
(III)).   
Since AOXRosa26 mice did not show any obvious phenotypic difference from 
wild-type, I hypothesized that any minor physiological modification caused by 
AOX expression might nevertheless be detectable at the metabolic level. To 
test this idea, I used metabolomic analysis, in collaboration with V. Velagapudi 
and J. Nandania, on heart and skeletal muscle tissues that were selected due 
to their dependence on mitochondrial energy compared with other tissues. 
Principal Component Analysis (PCA), performed by Dr. V. Velagapudi and J. 
Nandania, of total measured metabolites confirmed that AOX-expressing 
tissues, both skeletal muscle and heart, had a similar metabolite profile as 
wild-type tissues (figure 2C and S2H of paper (I)). The lack of any observable 
biochemical disturbance in AOXRosa26 mice indicates that the expressed AOX 
is benign under steady-state (unstressed) conditions in transgenic mice. 
However, it is predicted to be activated under conditions where the 
concentration of ubiquinol rapidly increases or mitochondrial complex III 
and/or IV is impaired, as has been observed in a mouse sepsis model (Mills 
et al., 2016). Therefore, the heart metabolome was also analyzed in Cardio 
AOX mice: the relevant data are presented in a later section (5.3.4 - f), in the 
context of my studies of the effect of AOX on two cardiomyopathy models. 
 
 
5.1.5. The Primary phenotyping screening at the German Mouse Clinic 
To test whether any other metabolic or physiological abnormalities were evident in 
AOXRosa26 mice, I collaborated with the German Mouse Clinic (Helmholtz Zentrum 
mϋnchen, GMC) to perform a detailed phenotyping. My collaborators measured over 
350 different parameters and extensively phenotyped the mice over a period of 14 
weeks, as summarized in figure 12. 
AOXRosa26 mice showed only very small (and statistically non-significant) differences 
in physical performance from wild-type mice (complete GMC data is available online, 
link provided in I). They did not differ in measurements of physical activity, including 
rotarod and grip strength analysis, with only a minor trend towards decreased 
locomotor activity in the modified SHIRPA test. 
54 
 
AOXRosa26 mice also showed a trend towards decreased hearing sensitivity, 
particularly at higher frequencies, but again this was not statistically significant. Other 
parameters where AOXRosa26 mice showed subtle, but generally non-significant 
differences from wild-type mice were: 
a) mild decrease in LV mass in both sexes, as measured by echocardiography; 
b) decrease in eye size in males, as measured by laser interference biometry; 
c) mild increase in plasma fructosamine levels in both sexes and 
d) sex-dependent changes in immune cell populations, based on flow 
cytometry, where transgenic males had increased NK cells and a high 
representation of CD44 high and CD11b-expressing NK cells, whereas females 
had increased CD11c-expressing monocytes and B cells  
Except for these parameters, AOX transgenic mice did not differ from wild-type mice 
in any other phenotypic measurements, including body weight, size and shape, 
cardiac function, rectal body temperature, metabolome and sensitivity to pain. A 
detailed report from the German Mouse Clinic is available online (see Materials and 
Methods, III). 
In summary, from all the measurements made by myself and in collaboration with 
others, including the GMC, I found that AOX expression does not significantly affect 
the physiology and metabolism of mice under standard laboratory conditions, nor in 
an age- or sex-dependant manner. However, my analysis did not include all possible 
parameters that could be affected in mice over their lifetime, which would be much 
more laborious to execute and not practically feasible. However, specific issues may 
need to be addressed in the future if AOX is to be considered as a therapeutic agent. 
In addition to the above, experiments done under contract by Luria Scientific 
Industries, Herzliya, Israel, showed that AOXRosa26 mice were also resistant to 
cyanide, when administered via IP at a concentration of 8.5 mg/Kg weight of the 
mouse, whereas 50% of wild-type mice did not survive this dose of the poison (figure 
5 of paper (I)).  
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In conclusion, I report in (I) that AOX can be successfully expressed in the mouse 
and, when expressed, it does not alter the general physiology of the animal compared 
to wild-type littermates, even though the protein is enzymatically active and provides 
protection against cyanide. These initial studies were a crucial first step before using 
the AOX mice in combination with disease models and other stresses.  
Figure 12: Schematic of experimental design followed in the German Mouse Clinic. 
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5.2 Impact of AOX expression in mice under dietary stress 
Although I was unable to detect any phenotypic deviation from wildtype in AOXRosa26 
mice, Drosophila melanogaster transgenically expressing AOX were previously found 
to exhibit a very mild phenotypic difference from wild-type flies in the form of a slight 
developmental delay and slightly exaggerated weight loss of adult flies (Fernandez-
Ayala et al., 2009). This could imply that AOX might be partially active in the 
transgenic flies, resulting in a less efficient use of available nutritional sources 
compared to non-transgenic or wildtype files. A follow up study (Saari et al., 2019) 
where AOX flies were cultured in a nutrition-deprived medium, containing only 3.5% 
yeast and 5% glucose plus agar and antimicrobials, maintained at temperatures 25 
°C or 26 °C, resulted in a dramatic loss (> 80%) of developing flies at the pupal stage, 
whereas control flies eclosed normally under the same conditions. 
These data, indicating a potentially severe impact of nutritional modification on AOX-
expressing animals, provided me with the motivation to study the impact of AOX on 
mice that were also subject to dietary stress. To this end, I subjected AOXRosa26 mice 
to diets containing high fat and/or low carbohydrate content, and measured relevant 
physiological parameters. 
To study how the combination of AOX expression and fat-rich diets affects phenotype, 
I administered two different kinds of fat-rich diet to AOXRosa26 mice and wild-type 
littermates. These were:  a) HF-60, where 60% of total calories come from fat and b) 
Ketogenic diet, where 90% of total calories come from fat with almost none 
(approximately 0.5%) derived from carbohydrates. Mice fed with a standard chow diet 
were used as controls, where only 18% of total calories are from fat and 58% from 
carbohydrates. The critical difference between the two fat-rich diets, except the 
amount of fat, is the amount of carbohydrates. Lack of carbohydrates in the ketogenic 
diet affects glycolysis, making gluconeogenesis the only source to maintain the body's 
glucose levels. Furthermore, the primary macronutrient of the ketogenic diet is fatty 
acids, which are catabolized by β-oxidation to acetyl-CoA, and then via the TCA cycle, 
both of which take place in mitochondria. Thus, studies with prolonged administration 
of ketogenic diet have often shown increased mitochondrial biogenesis. On the other 
hand, under a high-fat diet, mice usually gain weight due to the storage of much of 
the consumed fat in adipose tissue. Prolonged administration of high-fat diet has been 
shown to interact with mitochondrial dysfunction, especially in skeletal muscle 









The effects of these fat-rich diets on mice were measured using different parameters, 
as described in the following sections; 
 
5.2.1. Body weight 
Mice exposed to either of the high-fat diets for a prolonged period gained excess 
weight when compared with chow-fed mice. AOX expression did not affect weight 
gain except for a slight but statistically significant difference on ketogenic diet, where 
AOX-expressing mice weighed less, on average, than their wild-type littermates 
between the ages of 16 and 34 weeks (figure 13). However, both genotypes exhibited 
a relatively wide variation in weight on the ketogenic diet, at every time point when 
measured. I hypothesized that this could possibly be due to behavioral interactions 
between males caged together affecting feeding and/or physical activity. Mice are, in 
general, territorial, and tend to form social hierarchies and even exhibit aggressive 
behavior towards their ‘cage-mates’ (Horii et al., 2017). Such traits affect the behavior 
of mice, including eating and physical movement, which would in-turn affect the 
energy expenditure that could influence weight gain or loss. In order to investigate 
this further, I repeated the ketogenic diet experiment in a different facility where the 
mice were caged individually. In this smaller scale experiment, I observed much less 
variation in weight within the groups but, interestingly, the small difference between 
the genotypes was in the opposite direction to that observed in the first experiment. 
In the second trial, the AOX mice weighed slightly more than controls on ketogenic 
diet (figure 1C of paper (II)). Combined together, the slight weight differences 
exhibited by AOX mice on ketogenic diet were not systematic, despite being 
statistically significant in both experiments. 
Figure 13: Body weight (means ± SD) of wild-type (wt) and AOX-expressing male mice (n  6 for all 
groups) fed with either standard chow (chow), high-fat (HF-60), or ketogenic diets, as indicated. 
Highlighted gray areas indicate statistical significance (P < 0.05), two-way ANOVA followed by Tukey’s
multiple comparisons analysis - (left) between diets but not genotypes, (right) between genotypes. 
Figure reprinted from (II) under CC by 4.0 license. 
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5.2.2. Body composition 
In order to study the physiological response towards fat-rich diets in further detail, I 
measured the body composition of all mice using the DEXA imaging system, at the 
end of the diet experiment. As expected, mice fed with either of the fat-rich diets 
exhibited increased fat mass when compared to mice fed with chow diet (figure 2, II). 
In addition, the total fat percentage of mice fed with ketogenic diet was higher than 
that of mice fed with the HF-60 diet (figure 14), which was in accord with previous 
studies (Nilsson et al., 2016; Ahola-Erkkilä et al., 2010). Interestingly, the presence 
of the AOX transgene had a systematic effect on the lean mass of the mice, i.e. all 
AOX mice, irrespective of the diet, had less lean mass when compared to wild-type 
mice fed on the same diet. This could indicate a possible influence of AOX expression 
on the energy expenditure of mice, although further investigation is required to 
understand precisely how AOX expression affects the lean mass. Except for lean 
mass, AOX did not affect any other body-composition parameters measured; fat 
mass, fat %, bone mineral density, bone content and bone area (figure 2 of paper 
(II)). 
 
5.2.3. Cardiac function 
Previous studies have reported on cardiac dysfunction exhibited by mice exposed for 
a short period (4 weeks) to low carbohydrate, high fat (ketogenic-like) diets, proposed 
to be due to effects on energy metabolism from the altered amount of dietary fatty 
acids (Nilsson et al., 2016). Fatty acids are an essential source of fuel for the 
myocardium, but fatty acid overload results in cardiac dysfunction (Nilsson et al., 
Figure 14: Dual-energy X-ray absorptiometry (DEXA) analysis of muscle mass (lean mass) and
percentage of fat as indicated, on 48-week-old mice (n = 6 for all groups) of the indicated genotypes, 
fed on standard chow, high-fat (HF-60), or ketogenic diet as shown. Two-way ANOVA followed by
Tukey’s multiple comparison analysis, with lower-case letters denoting significantly different data 
groups in each panel. Figure reprinted from (II) under CC by 4.0 license. 
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2016). This is proposed to be mainly due to the excess accumulation of metabolic 
intermediates affecting fatty acid oxidation, the TCA cycle and calcium signaling, 
which eventually impairs mitochondrial function. I set out to test (a) if prolonged 
exposure to ketogenic diet would induce a similar (or even more severe) cardiac 
phenotype and (b) if there is any interaction with AOX, which could be attributable, 
for example, to its enzymatic activation. To study this, I measured the cardiac ejection 
fraction in AOX mice and wild-type littermates using echocardiography, performed on 
24 and 48-week old animals (16 and 40 weeks of ketogenic or standard chow diet 
exposure, respectively). At both time points, I observed a systematic though 
quantitatively modest difference with diet, where mice fed on ketogenic diet had a 
slightly lower ejection fraction compared to those fed on chow (figure 15).  
However, AOX expression did not affect the cardiac phenotype of mice fed on 
ketogenic diet. The measured cardiac parameters also did not show the same degree 
of variation within groups, as I observed with total body weight. This implies that 
cardiac function is not directly affected by total body weight, but rather by the 
metabolic state of the myocardium as influenced by diet. 
 
Figure 15: Echocardiographic assessment of the ejection fraction and left ventricular mass (LV mass) 
from 24- and 48-week-old mice (means ± SD, n = 6 for all groups) as shown. Difference in cardiac 
ejection fraction and LV mass was diet-dependent and not genotype-dependent. Two-way ANOVA,
with lower-case letters denoting significantly different data classes in each panel. Figure reprinted from





5.2.4. Gut microbiome 
Changes in dietary composition has been shown to systematically alter gut microbial 
populations, which has been suggested to be correlated with changes in intestinal 
energy balance (Turnbaugh et al., 2006; Wichmann et al., 2013). To test for such an 
effect in our wild-type mice, and to assess whether AOX has any influence on the 
population of gut microbes, I studied the gut microbiome in collaboration with A.M. 
Lyyski, Dr. L. Paulin and Dr. P. Auvinen. Fecal samples were collected at the end of 
the study from the mice fed either with ketogenic (first experiment) or chow diet and 
were processed for DNA extraction, PCR and sequencing, using primers detailed in 
Materials and Methods (II). Samples from the HF-60 group were not collected since 
there was no significant difference in body weight between AOX and wild-type mice 
in this diet group. The pool of 16S rDNA sequences was then analyzed for differential 
abundance of microbial populations with respect to diet, body weight and genotype. 
In order to effectively study the effect of independent factors affecting the gut 
microbiome, the groups were separated; a) by diet alone, irrespective of genotype, b) 
based on weight, categorized into normal (median and below), over-weight (3rd 
quartile) and obese (4th quartile), and c) based on diet and genotype (figure 16). The 
results were as summarized below, 
a) Comparing only the diets, chow vs ketogenic, the differences in microbial 
populations were significant across family, genus and taxonomic unit 
(OTU) classifications. This indicated a strong diet-dependent modification 
of the microbial population. 
b) When compared between different weight categories, irrespective of 
genotype, the microbiome population was still different across all three 
classifications. Interestingly, there were clear differences between the 
normal weight group and both of the heavy weight groups (over-weight 
and obese) in the top 20 genera (figure 16B). 
c) Between the genotypes (i.e. AOX vs wild-type), fed on ketogenic diet, 
there were no differences in the microbial populations at the level of 
families and genera but a few taxonomical units (OTU) were statistically 
significant. Considering only the genotype, irrespective of diets, there were 
a few significant differences at the genus and taxonomical unit (OTU) 
levels but the top 20 genera were not different (figure 16C). 
A detailed list of all microbiome data is provided in supplementary tables S5 
to S8 in (II). 
Acetatifactor Barnesiella Desulfovibrio Mucispirillum
Alistipes Bifidobacterium Desulfovibrionaceae UG                Odoribacter
Alloprevotella C Saccharibacteria UF         Erysipelotrichaceae UG Oscillbacter
Bacteroidales UF             Clostridiales UF Lachnospiraceae UG other taxa
Bacteroides Clostridium XIVa Lactobacillus Porphyromonadaceae UG
Ruminococcaceae UG 























In brief, AOX expression by itself only altered the population of a few microbial 
genera. Microbial populations were strongly correlated with diet and weight rather 
than genotype. 
In conclusion, I report in (II) that ubiquitously expressed AOX has only minor effects 
on the physiological changes induced by prolonged exposure to fat-rich diets. These 
findings can be interpreted in several different ways that are discussed in more detail 
in the next chapter. The most likely is that dietary stress induced by high-fat diets has 
no effect on mitochondrial complex III and/or IV, and therefore AOX remains 
unengaged. This has potential implications for the future use of AOX in therapy. 
Based on the results from my first two studies, AOX mice do not exhibit any 
phenotypic difference from wildtype, whether under non-stressful conditions (I), nor 
even under the stress of extreme dietary modifications (II). These findings prompted 
me to combine AOX-expressing mice with other disease models that exhibit more 
severe forms of physiological disruption, including overt mitochondrial dysfunction. 
Firstly, I used a mouse model for inflammatory cardiomyopathy, where chronic 
infiltration of monocytes leads to cardiac failure. Secondly, I used a mouse model 
where mitochondrial cIV is removed by genetic manipulation in the cardiomyocytes, 
leading to cardiac failure and early lethality. 
Figure 16: Distribution of top 20 gut microbial genera by abundance. (A) Comparing animals fed with 
chow versus ketogenic diet, (B) comparing different body weight groups by quartiles: normal weight (first
two quartiles, <45.1 g, overweight (o/w, third quartile, 45.2 to 55.8 g) and obese (fourth quartile,> 55.8 
g), (C) comparing animals by both genotype (wildtype, wt, or AOX-expressing) and diet. Taxa denoted
by genus, or family: UF – unidentified family, UG – unidentified genus, C – candidate phylum. Figure
reprinted from (II) under CC by 4.0 license. 
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5.3 Effect of AOX expression in a mouse model for inflammatory 
cardiomyopathy 
As discussed above (section 2.6), MCP1 overexpression in adult cardiomyocytes 
results in dose-dependent, lethal cardiac failure that has been suggested to involve 
ETC dysfunction and the consequent induction of excess mitochondrial ROS 
production in the respiratory chain. To test this idea, I combined Mcp1 mice with mice 
expressing AOX.  
In order to exclude any strain-specific effects, I first backcrossed the Mcp1 mice (i.e. 
the mice overexpressing Mcp1 specifically in adult cardiomyocytes), which were 
supplied originally on the FVB background, to the C57Bl6J/OlaHsd background for 8 
generations, before setting up experimental crosses.  
 
5.3.1. Survival phenotype 
I observed that the Mcp1-C57Bl6J/OlaHsd mice exhibited early lethality at 
approximately 25 – 30 weeks of age (red line, figure 17), which was similar to mice 
homozygous for Mcp1 overexpression in the FVB background (Kolattukudi et al., 
1998). The difference in survival also reflected the extent of cardiac dysfunction 
(figure 3B and 3C of paper (III)), analyzed by measuring the ejection fraction of mice 
by echocardiography. Interestingly, the cardiac ejection fraction of the Mcp1 mice was 
already compromised compared to wild-type littermates at 12 weeks of age and 
worsened as the mice aged. Note that only heterozygous Mcp1 mice were used for 
all my experiments, since they already manifest an early lethality phenotype. Although 
not studied, I assume that homozygous Mcp1-overexpressing mice in the C57Bl6/J 
background, would have suffered lethality at an earlier age than the heterozygous 
Mcp1 mice.  
Although Mcp1 is overexpressed only in the adult cardiomyocytes in the Mcp1 mice, 
there is a possibility that adaptations or maladaptations could occur in cell types other 
than cardiomyocytes, for example fibroblasts or macrophages, and these may also 
involve mitochondrial dysfunction. This could be an indirect result of cardiomyocyte 
loss, influencing the progression of contractile failure. In order to test this, I combined 
Mcp1 mice with ubiquitously AOX-expressing mice (AOXRosa26) as well as Cardio AOX 
mice, expressing AOX specifically in adult cardiomyocytes (figure 10). When crossed 
to mice expressing AOX constitutively, the timing of lethality of the Mcp1 mice did not 
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change (green line, figure 17). However, in combination with Cardio AOX, Mcp1 mice 
succumbed at a significantly earlier age, between 16-25 weeks (blue line, figure 17). 
Note that constitutive expression of Cre in adult cardiomyocytes also caused a lethal 
phenotype by itself (purple line, figure 17), but at a far later stage (after 35 weeks) 
and thus is judged not to have influenced the early lethality observed in Mcp1 + cardio 
AOX mice (blue line, figure 17) or any Mcp1-overexpressing mice. In order to maintain 
consistency in the read-outs, I used only male mice (n 5 per group) for this analysis. 
 
5.3.2. Cardiac function 
Echocardiographic analysis was done on males (n 5 per group) at 4-weekly intervals 
from 12 weeks until 20 weeks of age. All mice undergoing the procedure were 
anesthetized using a constant supply of 4 % isoflurane gas for no more than 20 
minutes in order to reduce any effect of isoflurane on the cardiac function. Ejection 
fraction (EF %), left ventricular diastolic volume (LV vol. diastolic) and left ventricular 
systolic volume (LV vol. systolic) were calculated from the images obtained and are 
represented as a measure of cardiac contractile function in the figures referred to 
below. 
Assessment of cardiac function by echocardiography showed that the Mcp1 mice 
already suffered a moderate cardiac contractile dysfunction at 12 weeks of age (red 
squares, figure 18B), as mentioned above. The average ejection fraction of wild-type 
mice was 61 %, which is considered to be within the standard range for a healthy 
adult mouse (Lindsey et al., 2018), whereas the ejection fraction of Mcp1 mice was 
Figure 17: Effect of AOX expression on the survival of MCP1-overexpressing mice. Survival curves of
mice of the indicated genotypes (wt – wild-type, Mcp1 – overexpressing Mcp1 in cardiomyocytes under
the control of the Myh6 promoter; global AOX – expressing AOX constitutively; cardio AOX –
expressing AOX specifically in cardiomyocytes, after activation of SNAPf-AOX by Myh6-cre, Myh6-cre
– expressing only cre in adult cardiomyocytes, and combinations as shown, n  10 for all groups except
those including Myh6-cre, where n  5). The survival curve for Mcp1 plus cardiomyocyte-specific AOX
was significantly different from that of Mcp1 alone, or together with global AOX (p < 0.0001, Log-rank
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significantly lower, at 44 %. AOX expression, both ubiquitous and cardiomyocyte 
specific, modestly ameliorated the contractile dysfunction. The mean ejection fraction 
of Mcp1 mice with global (AOXRosa26) AOX expression was 53 % and with 
cardiomyocyte-specific (Cardio AOX) expression was 51 % (green and blue squares, 
respectively, figure 18B). Although not restored to the wild-type level, they were both 
significantly different from Mcp1 mice at 12 weeks.  
At 16 weeks of age, constitutive AOX expression no longer provided any benefit to 
Mcp1 mice, since the mean ejection fraction was similar to that of mice 
overexpressing Mcp1 alone. However, at the same age, mice expressing 
cardiomyocyte-specific AOX had an exacerbated contractile dysfunction compared to 
the Mcp1 mice (figure 18B). The poor cardiac contractile function may be considered 
a reflection of the early lethality exhibited by Mcp1 + cardio AOX mice. Due to the low 
number of survivors at 20 weeks of age, this group was not included for 
echocardiographic measurement at that time point. At 20 weeks of age, both Mcp1 
mice and Mcp1 + global AOX mice exhibited poor cardiac contractility compared to 
control mice, with mean ejection fraction (EF %) of 33 % and 38 %, respectively 
(figure 18B). 
Figure 18: AOX expression preserves cardiac ejection fraction at early age. (A) Systolic and diastolic
volume of the cardiac left ventricle (LV) of mice of the indicated genotypes, measured by ultrasound at 
12 and 16 weeks, as indicated (means ± SD, n  5 for all groups). (B) Cardiac ejection fraction (EF %)
computed for individual mice of the indicated genotypes and ages, means ± SD. Horizontal lines marked
with asterisks indicate significant differences (one-way ANOVA within an age point, applying Tukey’s




Mcp1 mice, at 12 weeks of age, had a significantly higher left ventricular systolic 
volume (red bar, figure 18A) when compared to wild-type mice, indicating that the low 
EF % was due to the poor contractility of the left ventricle. Mcp1 + cardio AOX mice, 
at this age, had a higher diastolic and systolic volume (blue bar, figure 18A), which 
was significantly different from wild-type mice but the ratio of diastolic to systolic 
volume was better than Mcp1 mice and thus gave a better EF %. At 16 weeks of age, 
all Mcp1-overexpressing mice, irrespective of AOX expression, had poor cardiac 
contractility as indicated by higher systolic volume (figure 18A). In addition, the left 
ventricular mass was not different between the groups, measured at 12 and 16 weeks 
of age (figure S2A, III). 
 
5.3.3. Physical parameters 
To test whether the cardiac contractile dysfunction, although only moderate at the 
early time points, would affect the physical performance of mice, I measured their 
endurance using a treadmill designed for rodents. This experiment was conducted 
later in the project and due to the lack of availability of cardio AOX mice they were 
not included in the experiment. The treadmill experiment performed at ages 12 and 
16 weeks showed no clear difference between Mcp1-overexpressing mice and 
controls, irrespective of AOX expression (figure S2C of paper (III)). In addition, their 
body weights were also indistinguishable from those of controls (figure S2B of paper 
(III)).  
 
5.3.4. Molecular parameters 
In order to investigate the underlying molecular mechanism of the cardiac phenotype 
induced by Mcp1 overexpression, and the impact of AOX expression thereon, I 
performed molecular analysis on the left ventricle of these mice. Since AOX 
expression, both global and adult cardiomyocyte specific, showed improvement in the 
cardiac function in Mcp1 mice at 12 weeks of age, I performed most of the molecular 






a) Ultrastructural assessment 
In a previous study, mitochondrial structural changes and disorganization of myofibrils 
in the cardiac tissue of the Mcp1 mouse model has been reported (Niu et al., 2009). 
Assuming these observations were made when the mice had already developed a 
measurable cardiac phenotype and given the fact that Mcp1 mice acquired a 
moderate cardiac dysfunction in my study (figure 18) at a very young age, I wanted 
to check if there were any ultrastructural changes in Mcp1 mice at 12 weeks of age, 
and if AOX expression affected it. I collaborated with Dr. U. Gärtner from University 
of Giessen, who performed the electron microscopy imaging (detailed information on 
the embedding and sectioning is provided in (III)). In order to maintain uniformity, I 
collected a piece of tissue from the same region of the left ventricle of the various 
mice studied, 3 per group. Note, for this experiment, the groups included mice of both 
sexes. 
From my analysis of the images, obtained from 2-3 different sections of left ventricular 
tissue, disoriented myofibrils were not visible in Mcp1 mice at this age (12 weeks). 
However, several dense structures containing mitochondria, putatively 
mitophagosomes or autophagosomes, were clearly visible in Mcp1 mice (figure 19A). 
There were almost none of these dense structures visible in Mcp1 + global AOX mice. 
A proper quantification of these dense structures or mitochondrial size/cristae count 
would ideally include the examination of several more regions, which would be labor 
intensive and time consuming, but might eventually yield additional insights. For this 
reason, I did not follow up this approach. In addition, at 12 weeks of age, both Mcp1 
+ global AOX and Mcp1 + cardio AOX mice exhibited similar cardiac function and so 
I did not anticipate a major difference between them at the ultrastructural level and 
thus omitted Mcp1 + cardio AOX mice from ultrastructural analysis.  
 
b) Mitochondrial respiration analysis 
To investigate whether the presence of putative mitophagosomes were a reflection 
of mitochondrial dysfunction, I measured the respiratory capacity of isolated 
mitochondria from the left ventricle of male mice (n≥3 per group) aged 12 and 16 
weeks. I observed a clear decrease in cI- and cII-mediated respiration in heart 
mitochondria from Mcp1 mice compared with controls at 12 weeks of age (figure 19B). 
At this age, heart mitochondria from Mcp1 + global AOX mice did not show any 
significant improvement in cI-mediated respiration but did exhibit better preserved cII-
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mediated respiration. Heart mitochondria from Mcp1 + cardio AOX mice at 12 weeks 
of age showed a similar trend in cII-mediated respiration compared with the Mcp1 
mice, although this did not reach statistical significance.  
Analysis of heart mitochondria from Mcp1 and Mcp1 + global AOX mice at 16 weeks 
of age exhibited a very similar pattern of mitochondrial respiration, whereas cI-
mediated respiration was significantly lower in both these groups compared with wild-
type mice. However, at this age, the cII-mediated respiration was still better preserved 
in Mcp1 + global AOX mice when compared with Mcp1 mice (figure 19B). 
 
c) Protein expression analysis 
To test whether the compromised mitochondrial respiration reflects a loss of 
mitochondrial OXPHOS complexes, I studied the protein expression levels of 
representative subunits of each OXPHOS complex, using the commercially available 
OXPHOS antibody cocktail, and other mitochondrial markers using tissue lysates 
from the left ventricle of 12-week old male mice (n=5 per group). Western blots 
showed that several subunits, notably of cI and cIII, were mildly decreased in all 
groups of Mcp1-overexpressing mice, irrespective of AOX expression, when 
Figure 19: Effect of AOX on mitochondrial structure and respiration. (A) Transmission electron 
micrographs of cardiac left ventricle from 12-week old animals of the indicated genotypes and
treatments. Scale bars as indicated: lower images represent higher magnification of portions of those 
shown in the top line. The dark inclusions in close proximity to mitochondria, seen in cardiomyocytes 
from the Mcp1-overexpressing mice, are interpreted as secondary lysosomes. >12 such sections were 
analysed from mice of each genotype (2–3 sections from each of 2 blocks from 3 individuals). Multiple 
such inclusions were seen in the sections from Mcp1 mice, but not from controls or from mice expressing
global AOX. Note also the less densely packed cristae in mitochondria from the Mcp1-overexressing
mice, which was evident in all sections analysed. (B) Respirometry of mitochondrial suspensions from 
heart tissue of mice of the indicated genotypes, driven by cI- (pyruvate, glutamate and malate in the 
presence of ADP) or cII-linked (succinate in the presence of rotenone) substrates as shown. Figure
reprinted from (III) under CC by 4.0 license. 
68 
 
compared to wild-type (figure 5C of paper (III)). However, quantification of these 
bands by densitometry found that these differences were not statistically significant 
in most cases (figure S3A, III) except for subunit ATP5A of cV, which was significantly 
lower in Mcp1 + global AOX and Mcp1 + cardio AOX when compared to wild-type 
controls (figure S3A of paper (III)). 
In addition, I did not observe any significant difference in the level of the mitochondrial 
outer-membrane protein, porin, in all Mcp1-overexpressing mice when compared to 
wild-type (figure 5C and S3A of paper (III)). This implies that there is no severe loss 
of mitochondria in the left ventricle of Mcp1 mice at 12 weeks of age. 
Interestingly, the levels of GAPDH, a glycolytic enzyme, were significantly higher in 
all Mcp1-overexpressing mice when compared to wild-type (figure 5C and S3A of 
paper (III)), indicating a possible increase in the capacity of the glycolytic pathway in 
these mice. 
Western blot analysis of the left ventricle of 16 week old mice showed a similar trend 
for the respiratory chain subunits and for GAPDH (figure S3B of paper (III)) between 
all Mcp1-overexpressing mice and controls. 
 
d) RNA expression analysis 
To further investigate the changes in gene expression, I performed RT-qPCR analysis 
on the left ventricle of 12-week old mice (males, n=5 per group). My analysis provided 
evidence of various kinds of stress signaling and consequent tissue remodeling 
(figure 20), as follows:  
I. mRNA for the immunomodulatory cytokine IL10 was increased, consistent 
with an inflammatory state   
II. markers for mitochondrial stress, Fgf21 and Gdf15 were elevated, strongly 
indicating mitochondrial dysfunction 
III. a switch towards a fetal-like gene expression pattern was detected, where 
beta myosin heavy chain (Myh7) and Gata4 mRNAs were upregulated and 
that for alpha myosin heavy chain (Myh6) downregulated, consistent with the 
initiation of cardiac remodeling.  
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In addition, contradicting my initial hypothesis that oxidative stress observed in 
Mcp1 mice could emanate from mitochondria due to respiratory dysfunction, RNA 
for Sod2, a mitochondrial ROS detoxifying enzyme, was downregulated. When 
combined with AOX, whether global or cardio, the altered expression levels of all 
of these markers was not significantly different from that in the hearts of Mcp1 
mice without AOX (figure 20).  
 
e) Reduced Q pool measurement 
Results from all the experiments mentioned above indicate a clear cardiac phenotype 
induced by Mcp1-overexpression already at 12 weeks of age. Interestingly, the 
cardiac function and mitochondrial cII-mediated respiration of mice overexpressing 
both Mcp1 and AOX were significantly different from mice overexpressing Mcp1 only. 
These data suggest that the physiological and molecular differences observed in 
Mcp1 + global AOX and Mcp1 + cardio AOX mice, in comparison to Mcp1 mice at 12 
weeks, were due to the activation of AOX. However, this activation, i.e. participation 
of AOX in respiratory electron flow, requires certain specific conditions in the 
mitochondria, in particular the accumulation of the CoQ electron carrier in the reduced 
form (ubiquinol) above a certain threshold, which is approximately a ratio of 0.4 to the 
oxidized form (Dry et al., 1989, Dogan et al., 2018).  
To test if the compromised respiratory capacity observed in Mcp1 mice favored 
conditions that were sufficient for AOX activation, I studied the CoQ levels in the left 
Figure 20: Effect on mRNA expression resulting from overexpression of Mcp1 and AOX. RT-qPCR
analysis of levels of the indicated RNAs in cardiac left ventricle of 12-week old mice of the genotypes
shown, in each case normalized to the value for wild-type (means ± SD, n = 5 for each genotype).
Horizontal lines marked with asterisks indicate significant differences between wild-type and other
groups (one-way ANOVA with Tukey post hoc HSD test; **, ***p < 0.01, 0.001, respectively). Figure
reprinted from (III) under CC by 4.0 license. 
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ventricle of 12-week old mice, in collaboration with Dr. G. Brea-Calvo, who performed 
the quinone measurements. The ratio of the reduced to the oxidized form of CoQ9, 
which is the most abundant quinone in mice, was higher than in wild-type mice but 
did not reach the optimal level for AOX activation, i.e. 0.4 or above (figure S3C of 
paper (III)). However, the reduced form of CoQ10 significantly accumulated in Mcp1 
compared to wild-type mice. Surprisingly, global AOX expression did not decrease 
the proportion of reduced CoQ10 in Mcp1 mice, but cardio AOX did, almost to the 
levels of wild-type mice (figure 5D of paper (III)). 
 
f) Global metabolomic analysis 
To investigate the impact of the above-mentioned changes upon global metabolism, 
I collaborated with the metabolomics core facility in the University of California, Los 
Angeles (UCLA) to perform a metabolomic flux analysis on 12-week old mice of the 
different genotypes. Three mice per group, mixed sexes, were administered 13C6 
glucose intraperitoneally before sacrificing by cervical dislocation and harvesting the 
left ventricle. The control groups were administered 12C6 glucose before sacrifice and 
tissue harvest. Administration of glucose and tissue harvesting were done by myself, 
whereas metabolomic flux analysis was performed on the tissue extracts by the UCLA 
metabolomics unit. From Principal Component Analysis (PCA) of the labeled 
metabolites, it was clear that Mcp1 mice grouped separately from the control mice 
(green points, figure 6 of paper (III)). Mcp1 + global AOX mice clustered along with 
Mcp1 mice (red points, figure 6 of paper (III)) but Mcp1 + cardio AOX mice formed a 
separate group from the rest (blue points, figure 6 of paper (III)). The clear difference 
between Mcp1 + cardio AOX mice and Mcp1 + global AOX mice at the metabolomic 
level correlates with the rapid progression of cardiac contractile dysfunction in Mcp1 
+ cardio AOX mice at 16 weeks of age and early lethality when compared to Mcp1 + 
global AOX mice.  
Taken together, these results support previously published data pointing towards 
adverse cardiac remodeling induced by Mcp1 overexpression, with AOX expression 
providing only a transient protection against this process. However, cardiomyocyte-
specific AOX expression proved to be detrimental to the Mcp1 mice. Possible reasons 
for these apparently contradictory findings are discussed in chapter 6.  
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5.4 Effect of AOX expression in a mouse cardiomyopathy model with 
mitochondrial complex IV dysfunction 
To study the impact of AOX expression in a phenotypically more severe 
cardiomyopathy model where the mitochondrial respiratory system is directly 
affected, I used Cox10fl/fl mice (Diaz et al., 2005), where exon 6 of the Cox10 gene is 
floxed. COX10 is essential for the biosynthesis of heme a, the active core of 
mitochondrial cIV. Therefore, lack of the enzyme should prevent the biosynthesis of 
active cIV, thus blocking respiratory electron flow at the final step. A previous study 
(Dassa et al., 2009) reported that COX deficiency induced by COX10 knockdown in 
human fibroblasts could be complemented by Ciona AOX expression. To test if this 
would work in heart in vivo, i.e. at the whole organism level, I used genetic crosses 
to combine the SNAP-AOXRosa26 mice with Cox10fl/fl and the adult cardiomyocyte-
specific Cre driver used in the MCP1 experiments described above, Myh6-Cre. A 
detailed list of the crossing scheme and progeny is provided in table S5 of paper (III). 
To test if Cox10 KO in the adult cardiomyocytes would cause a phenotype in mice, I 
made the crosses described below: 
Cox10(fl/wt) X Cox10(fl/wt); tg(Myh6-Cre/wt) 
and 
Cox10(fl/fl) X Cox10(fl/wt); tg(Myh6-Cre/wt) 
From my initial assessment, Cox10 KO in adult-cardiomyocytes caused early lethality 
(pink line, figure 21A) in mice where the maximum survival was 21 days post-natally, 
i.e. before weaning.  
To test if AOX expression in these mice would affect the phenotype, I made crosses 
to generate Cox10 KO mice also expressing AOX, as described below: 
Cox10(fl/fl) X Cox10(fl/wt); Aox(+/wt); tg(Myh6-Cre/wt) 
In the above mentioned cross, Aox(+/wt) describes heterozygous SNAP-AOXRosa26 
mice. Mice positive for AOX expression and lacking COX10 in adult-cardiomyocytes 
did not show any difference in survival or phenotype (turquoise green, figure 21A) 




Surprisingly, from my qualitative assessments of embryos and newborn pups, no 
Cox10 KO mice, irrespective of AOX expression, showed any distinguishable 
morphology or developmental delay compared to the controls. This indicates that the 
total loss of COX10 does not affect development, but results in a sudden and rapid 
onset of lethality in mice once born. 
On the other hand, heterozygous knockout of Cox10 in adult cardiomyocytes did not 
cause a severe phenotype, such as seen in the homozygous knockout mice. These 
mice seemed indistinguishable from control mice, and did not show any behavioral 
phenotype. However, they did suffer a mild but statistically significant cardiac 
contractile dysfunction at 12 weeks of age (figure 21C). Mice expressing AOX in the 
Cox10 heterozygous knockout background manifested slightly better cardiac 
function, represented by cardiac ejection fraction, than the heterozygous Cox10 
knockout mice (figure 21C).  
Figure 21: AOX did not have a major effect on the phenotype induced by Cox10 knockout in 
cardiomyocytes. (A,B) Survival curves of mice of the indicated genotypes: Cox10 /  – cardiomyocyte-
specific knockout of Cox10, i.e. mice were Cox10fl/fl plus Myh6-cre+ ; Cox10 /  + cardio AOX – 
cardiomyocyte-specific knockout of Cox10 plus activation of SNAPf-AOX by Myh6-cre (both 
heterozygous); Myh6-cre – Myh6-cre+  only, no cre – control mice lacking Myh6-cre, cardio AOX – 
cardiomyocyte-specific activation of SNAPf-AOX by Myh6-cre, both hemizygous; Cox10+  – 
cardiomyocyte-specific heterozygous knockout of Cox10, i.e. mice were Cox10+/fl and Myh6-cre+ ;
Cox10+  + cardio AOX – cardiomyocyte-specific heterozygous knockout of Cox10, i.e. mice were 
Cox10+/fl and heterozygous for both Myh6-cre and SNAPf-AOX. n  6 for all groups. (C) Cardiac 
ejection fraction (EF %) computed for individual mice of the indicated genotypes and ages, means ± 
SD, by echocardiography. Horizontal lines marked with asterisks indicate significant differences (one-
way ANOVA within an age point, applying Tukey’s post hoc HSD test; *, **, ***p < 0.05, 0.01, 0.001, 
respectively). Figure reprinted from (III) CC by 4.0 license. 
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Long-term evaluation of these mice was not possible as the chronic expression of 
Cre in cardiomyocytes by itself was cardiotoxic, as has been reported previously 
(Pugach et al., 2015), resulting in cardiac dysfunction and lethality in all mice 
expressing Myh6-Cre (figure 21B) with a mean survival of about 45 weeks. The effect 
of Cre expression on cardiac function was already visible at 24 weeks of age and so 
we discounted any difference observed in cardiac ejection fraction from this time point 
on.  
Since the effect of Cre expression was observed only from age 24 weeks, it is unlikely 
that the early lethality phenotype observed in Cox10 KO mice was due to Cre 
expression. Instead, I propose that the the early lethality phenotype was caused 
solely by the lack of COX10 in the adult-cardiomyocytes, although an interaction 
between the two genetic manipulations in combination cannot be excluded. 
In conclusion, from this study I report that;  
a) cardiomyocyte-specific knockout of Cox10 causes early lethality in mice.  
b) heterozygous knockout of Cox10 does not cause a severe phenotype in mice, 
although a mild cardiac contractile dysfunction is observed at 12 weeks of age. 





Since the ancient time of endosymbiosis, mitochondria have evolved into an integral 
part of the eukaryotic cell contributing to and coordinating cellular homeostasis via its 
multiple functions. Due to the tightly interconnected metabolic pathways operating in 
mitochondria, i.e. the products of one pathway being the substrate or co-regulators 
of others, fluctuations in one pathway often induce a negative (or positive) feedback 
on others. This can result in a disturbed metabolic homeostasis. Such dysfunction 
has been shown to be particularly detrimental for cells that are heavily dependent on 
mitochondria for energy, e.g. cardiomyocytes (reviewed by Lopaschuk et al., 2010; 
Lesnefsky et al., 2016; Hoppel et al., 2017). Under physiological conditions, 
mitochondrial function in the cardiomyocytes is maintained to match the energy 
demand by regulating mitochondrial biogenesis and dynamics. For example, 
disruption of the fission/fusion machinery has been shown to be detrimental to the 
cell (Chen et al., 2011, reviewed by Ong et al., 2013, Piquereau et al., 2013 and 
Vasquez-Trincado et al., 2015). In chronic conditions of mitochondrial dysfunction, 
accumulation of these stresses increases the possibility of cell death and tissue 
damage (reviewed by Rosca et al., 2014).  
Defects in the OXPHOS system not only compromise net ATP produced by 
mitochondria but can also impair flux in metabolic pathways, cause excess production 
of ROS and dysregulate cell signaling, thereby affecting cellular function at multiple 
levels. For example, a defective ETC could result in the release of cytochrome c into 
the cytosol, triggering apoptosis (Liu et al., 1996, reviewed by Cai et al., 1998). Basal 
amounts of ROS are required for cellular function (Owusu-Ansah et al., 2009, Tormos 
et al., 2011). However, when accumulated in larger quantities, they produce 
detrimental effects by targeting other molecules and by signaling the induction of 
autophagy (reviewed by Zhang et al., 2007; Schieber et al., 2014).  
The cell-type specificity of these defects, plus the variable heteroplasmic load of 
defective mitochondria, are some of the major factors responsible for the wide 
variation in age of onset and severity of clinical symptoms in mitochondrial disorders 
(Khan et al., 2015). The complexity of mitochondrial diseases and the overlapping 
nature of clinical presentations has made early diagnosis and treatment highly 
problematic. With advances in molecular tools and techniques in the past decades, 
several research models have been generated to investigate the underlying 
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molecular mechanism of complex mitochondrial diseases (reviewed by Wallace, 
2001; 2002; Rudolph et al., 2016). 
In this doctoral thesis project, I used such a model where Ciona AOX was genetically 
engineered for expression in mice. This has allowed me to study the impact of 
OXPHOS dysfunction under dietary stress and in animal models of heart failure.  
 
6.1. Impact of AOX expression in mice 
Despite its presence in phyla composed of slow-moving and sessile organisms, 
among the metazoans, the reason for the evolutionary loss of AOX in vertebrates and 
insects is not understood. Changes in environmental conditions, for example, a 
decrease in atmospheric sulfide levels (Weaver, 2019), or gene loss events in an 
environment where AOX provided no reproductive or survival advantage (McDonald 
et al., 2009) have been previously postulated to account for this evolutionary loss. In 
addition, transgenic flies expressing AOX showed a modest developmental delay, as 
well as weight loss in young adult flies, indicating a possible interference by AOX in 
the efficiency of catabolism (Fernandez-Ayala et al., 2009). Such an effect, although 
minor, could have a cumulative and detrimental impact with age. Although AOX does 
not interfere with the standard ETC under conditions that are favorable for its 
enzymatic activity, it will result in less ATP production when compared to the standard 
pathway, provided a portion – even a small one – of the respiratory electron flow from 
cI is diverted into it. Such a diversion would be detrimental for cells with high energy 
demand, e.g. cardiomyocytes. Such a phenomenon might underlie the loss of AOX 
in higher, motile animals during evolution. However, the potential benefits of AOX-
mediated respiration in diseases where the cytochrome pathway is defective has 
inspired its investigation as a therapeutic option.  
Safe and stable expression of transgenic AOX in mice was first reported by El-Khoury 
et al., (2013). However, the use of lentiviral transduction resulted in multiple 
integrations of the AOX coding sequence. Although the founder mice and first 
offspring showed strong and stable expression of AOX, the gene expression levels 
and patterns became irregular in succeeding generations (personal communication 
from prof. Pierre Rustin and Dr. El-Khoury), making it impossible, on a practical level, 
to maintain the mouse line and combine it with other disease models. Thus, a 
genetically tractable mouse with a single integration of the AOX coding sequence was 
later generated to make efficient use of AOX mice (I). The characterization of this 
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model was the starting point for the work described in this thesis. I went on to 
characterize, in addition, a second model, in which the AOX transgene was 
conditionally activatable by the removal of a floxed cassette carrying the SNAP coding 
sequence (section 2.8 and (III)). This second model was mostly studied in 
combination with the Myh6-cre driver, activating AOX expression in adult 
cardiomyocytes. The activation of AOX expression specifically in the heart (figure 10), 
serves as a validation for the use of the second model in combination with mice 
expressing Cre in diverse tissue-specific patterns, so as to restrict AOX expression 
accordingly.  
Transgenic AOX mouse models, both ubiquitous and cardiac expressing (I) and with 
expression specifically in adult cardiomyocytes (III), did not show any detrimental 
phenotype under normal physiological conditions. Multiple lines of evidence from my 
observations support this conclusion, as described below. 
a) If AOX was enzymatically active, the OXPHOS pathway should be affected 
thereby affecting metabolic homeostasis in diverse ways. However, 
metabolite analysis of heart (figure S2H of paper (I)) and muscle tissue (figure 
22) showed no difference between wildtype and transgenic AOX mice. It is a 
very relevant finding since several studies have shown evidence for metabolic 
disturbances, especially involving lipid and carbohydrate metabolism, due to 
mitochondrial respiratory defects (Hansson et al., 2004, Deepa et al., 2018, 
Rajendran et al., 2019). Although this measurement was done only once and 
on young mice (AoxRosa26 – males, 8-weeks-old and SNAP-AOXRosa26 – males 
and females, 12-weeks-old), the results indicate a lack of impact of AOX on 
the overall metabolism of mice in this age range. In addition, in a different 
study conducted by Rajendran et al. (2019), AOX expression was shown not 
to alter the metabolite levels in the heart, liver and kidneys of 150-day-old 
mice. This is also reflected in other parameters measured, including total body 
weight, fat content, muscle mass, bone composition and blood metabolites of 
mice at various measured time points (figure 13, 14, 15 and 22). Taken 
together, these results show that AOX does not affect the metabolic 





b) Branching the ETC by the introduction of AOX should result in less ATP 
production due to the decreased contribution of electron flow from the two 
proton-pumping complexes, cIII and cIV. This should have a more noticeable 
impact on tissues with higher energy demand, like the heart. The cardiac 
ejection fraction showed no difference between wild-type mice and transgenic 
AOX mice under normal physiological conditions (figure 11, 15 and 18). The 
implication is that AOX does not contribute substantially to electron flow under 
these conditions. 
c) The rates of respiration of isolated mitochondria from different tissues were 
nearly identical between wild-type and transgenic AOX mice, unless treated 
with a cIII inhibitor, antimycin A or cIV inhibitors, such as cyanide or azide, for 
which AOX conferred robust resistance in all tissues except adult brain (figure 
11 and 19). If AOX was constitutively active enzymatically, the maximum 
coupled respiration rate of isolated mitochondria should have been 
significantly different in tissues from the transgenic mice. The finding of 
unchanged respiration in vitro was also supported by a lack of difference in 
the expression levels of subunits of the endogenous respiratory complexes in 
transgenic mice, based on the idea that compromised functional activity of cIII 
Figure 22: AOX expression does not affect the normal physiology of mice. (A) Total body weight (mean
±s.d.) of hemizygous AOXRosa26 (AOX +/-) and wild-type mice of the sexes and time (weeks of age) 
indicated, n 8 for each sex and genotype analyzed. (B) Principal component analysis of metabolome 
data from skeletal muscle of hemizygous AOXRosa26 (red circles) and wild-type littermate control mice
(green circles; n=6 for both groups. (C) Glucose, lactate and ketone-body concentrations measured
from 48-week-old mouse tail-vein blood (n 4) of the indicated genotypes, fed on standard chow, high 
fat (HF) or ketogenic diet as indicated. Statistical analysis was performed using Student’s t-test for (A)
and Two-way ANOVA for (C), revealed no difference between genotypes. Figure reprinted from (I) and 
(II) under CC by 4.0 license. 
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and cIV might be expected to have had a negative (or positive) feedback on 
the expression levels of their subunits (figure 9; figure 5C of paper (III)). 
However, I only measured the expression of one subunit representing each 
OXPHOS complex. The observation should therefore be considered as 
indicative rather than conclusive. A more comprehensive study could be 
undertaken to settle the issue. 
d) Additionally, AOX expression by itself did not cause lethality or any other gross 
phenotype in mice during the observed time period (figure 17). Furthermore, 
the extensive phenotyping performed by GMC showed no major differences 
between wild-type and transgenic AOX mice. 
These various observations indicate that the overall impact of AOX expression is 
phenotypically undetectable at the whole-organism level, under normal physiological 
conditions. Thus, AOX can be considered to be functionally inactive in mice under 
non-stressed and moderately stressed conditions, unless interfered with by 
cytochrome-targeted toxins, such as antimycin A or cyanide. Even under moderate 
stress, conferred, for example, by treadmill running (I) or fat-rich diets (II), (discussed 
further in the next section), I was unable to demonstrate any convincing phenotypic 
deviation from wild-type. This inference also supports previous observations in 
human cell-culture models, fruit flies and lentivirally transduced mice (Hakkart et al., 
2006; Fernandez-Ayala et al., 2009; El-Khoury et al., 2013). However, all of the 
measurements in mice, excluding those related to the heart, but including the 
extensive phenotyping by the GMC, were not repeated. It is also worth noting that the 
GMC phenotyping tests were conducted on young mice, and at a single age point. A 
more extensive future study could reveal accumulated effects of AOX expression over 
time, where minor variations could eventually be revealed. To resolve this question, 
a longitudinal measurement of at least the major parameters needs to be 
implemented over the lifetime of the animal. Note, however, that such an 
experimental set-up might be ethically challenging, considering the 3R principle for 
animal experiments. The 3R principle, representing replacement, reduction and 
refinement (Russel et al., 1959) guides researchers in planning and conducting 
animal experiments. Its major focus, as it says, is to replace animals with other study 
models; to avoid excess use of animals; and to treat them as humanely as possible. 
Additionally, such a longitudinal measurement may also not be particularly 
informative, unless AOX is to be developed as a therapy to treat chronic diseases 
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that result from the cumulative effects of minor defects over time, involving either 
persistent stress or natural aging. 
 
6.1.1. Effect of long-term exposure to fat-rich diets 
Long-term exposure of mice to fat-rich diets, both HF-60 and ketogenic, resulted in 
body weight gain, increased fat mass, reduced bone mineral density and increased 
bone area. AOX-expressing mice showed a reduced body weight gain compared to 
the wild-type mice under ketogenic diet, however, the difference reversed when they 
were caged individually, as discussed below. Additionally, AOX expression also had 
a minor effect on the lean mass of the mice, in a diet-independent manner, and 
moderately altered the gut microbiota of both control- and ketogenic diet-fed mice. 
Except for these parameters, AOX expression did not affect any other parameter 
measured, including cardiac ejection fraction measured on mice fed with ketogenic 
diet. 
Long-term exposure of mice to high-fat diets induces a condition of chronic stress 
resulting in excessive weight gain, hyperglycemia, insulin resistance and altered 
cardiac parameters (Calligaris et al., 2013), leading to overt cardiac dysfunction (Che 
et al., 2018). Since mitochondria play a major role in the metabolism of carbon 
macronutrients, i.e. carbohydrates and fatty acids, the metabolic syndrome induced 
by long-term exposure to high-fat diets has been shown to produce specific effects 
on mitochondrial function and to result in increased mitochondrial H2O2 production 
(Anderson et al., 2019; review by Putti et al., 2015). Additionally, several independent 
studies have reported on the detrimental effect of high-fat diets on mitochondrial 
function (Sparks et al., 2005, Cormier et al., 2019, Jha et al., 2019, Xu et al., 2019). 
On the contrary, previous studies have also reported on the beneficial effects of 
ketogenic diet on a patient with Alpers–Huttenlocher syndrome (Santra et al., 2004) 
and a mouse model for mutated mitochondrial helicase TWINKLE (Deletor mouse; 
Ahola et al., 2010). However, efforts of using modified atkins diet to treat patients with 
mitochondrial myopathy (Ahola et al., 2016) proved to be detrimental, since the diet-
induced ketosis in patients, resulting in progressive muscle damage due to the 
already impaired mitochondrial respiratory chain activity (Ahola et al., 2016). Such 
conditions might be predicted to result in the engagement of AOX if, for example, a 
defective or overloaded ETC was part of the mechanism producing these effects. 
However, from my observations (II), fat-rich diet-induced phenotypes were almost 
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identical between wild-type mice and transgenic AOX mice. Small differences in body 
weight between AOX and wild-type mice under ketogenic diet were observed in an 
initial experiment, where transgenic AOX mice weighed slightly less compared to 
wild-type mice, possibly indicating an effect possibly attributable to AOX activation. 
This difference is similar to the observation in Drosophila (Fernandez-Ayala et al. 
2009), where AOX expression resulted in a slight decrease in the body weight of 
young flies, except that, in this case, the flies were maintained on a standard 
laboratory diet. As in flies, the observed weight differences in mice could reflect an 
alteration in overall catabolism, resulting from at least a partial activation of AOX. This 
implication is also suggested by the systematic decrease in lean mass, measured at 
the end of the study, associated with AOX expression in all diet groups tested (figure 
14). 
The huge variation in body weight within the diet groups disappeared in a follow-up 
experiment, in which the mice were individually caged. Moreover, the difference 
between the genotype groups in mean weight was in the opposite direction than in 
the first experiment, with transgenic AOX mice now slightly heavier than control mice. 
These observations suggest that differences in social interaction among mice can 
influence other relevant aspects of their behavior, including food consumption and 
activity, ultimately affecting their energy expenditure. My observation is consistent 
with previous reports where environmental factors such as, caging conditions, noise 
levels, animal handling have been shown to cause stress and abnormal behavior in 
rodents (Brown & Grunberg, 1996, Neely et al., 2018, reviewed by Sundberg & 
Schofield, 2018). If the small difference in weight gain between the genotype groups 
in the second diet experiment were indeed due to the activity of AOX, a causal 
relationship may be hypothesized between AOX activation and diet composition (or 
physical activity). However, in vivo measurement of AOX activity is not yet possible, 
and assays in vitro would be uninformative, since the exact metabolic conditions 
during exercise in vivo are not straightforward to simulate. AOX from other organisms 
can be activated by organic acids, including pyruvate (Millar et al., 1993), although 
this has not been established for the metazoan enzyme. Thus, the effects of diet on 
AOX activation remain to be studied. 
It should be noted that the activity of AOX can only complement defects of cIII or cIV, 
under conditions where ubiquinone in the reduced form has accumulated beyond the 
capacity of the cytochrome pathway to metabolize it (Dry et al., 1989, Dogan et al., 
2018). In steady-state conditions metabolic rate should match energy demand: but 
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chronic exposure to fat-rich diets may affect this metabolic balance due to increased 
availability of substrates. In such situations, substrate uptake may exceed the rate of 
catabolism, leading to accumulation of metabolic intermediates, including NADH and 
FADH2, which would not have formed under steady-state levels. Such an overload 
could directly affect reduction of cI and/or ubiquinol, with excess reduction leading to 
electron leak (reverse electron transfer) via cI, which has been proposed to be a 
possible mechanism for mitochondrial H2O2 production, initially as a superoxide 
(Anderson et al., 2019). In the same study, expression of mitochondrially targeted 
human catalase and administration of a small-peptide antioxidant, which localizes to 
the mitochondrial inner membrane, prevented diet-induced insulin insensitivity in 
mice. These results indicate a critical role of superoxide production in mitochondria, 
under high-fat-fed conditions, in the development of the phenotype. Assuming a 
similar condition was induced by chronic exposure of mice to the even more extreme 
ketogenic diet, AOX would have been enzymatically active, preventing the over-
reduction of ubiquinol, thereby limiting excess ROS production and consequent 
phenotypes. But the quantitatively minor difference between AOX transgenic and 
control mice reared on fat-rich diets suggests either the dietary stress was not 
sufficient to constantly maintain ubiquinol in an over-reduced state or that any AOX-
mediated energy deprivation may have been compensated by increased food intake. 
Since both the ketogenic diet, which is in paste form, and the HF-60 diet, which 
disintegrates due to high fat content, was quite difficult to be measured once added 
to the cage, food consumption by each individual mouse was not accurately 
measurable in this study. A proper way to study this would require controlled feeding 
and regular measurement of metabolic and physiological parameters.  
 
6.2. Partial rescue of Mcp1-induced phenotype by AOX 
The Mcp1 mouse model is engineered to constitutively express MCP1 under the 
adult-cardiomyocyte-specific Myh6 promoter (Kolattukudy et al., 1998). The 
constitutive expression of MCP1 results in cardiac failure as a consequence of 
chronic inflammation. Previous studies on Mcp1 mice, showing evidence for oxidative 
stress-induced cell death, accompanied by mitochondrial structural damage (Niu & 
Kolattukudi, 2009, Younce & Kolattukudi, 2010). Although ROS production in the 
inflammatory process is normally considered to be due to the activity of NADPH 
oxidase (Zeng et al., 2019), an involvement of the mitochondrial ETC cannot be 
excluded. Moreover, the observation that hyperoxia is able to block the development 
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of the inflammatory phenotype in Mcp1 mice (reported in the first portion of paper (III), 
to which I did not contribute data) provided an additional rationale for testing the ability 
of AOX to rescue the pathology.  
However, AOX provided only a transient rescue of the Mcp1-induced phenotype, 
which was lost as the mice aged. Furthermore, adult cardiomyocyte-specific 
expression of AOX exacerbated the phenotype in mice after 16 weeks of age. The 
accumulation of reduced ubiquinol, CoQ10, in Mcp1 mice (figure 5D of paper (III)) 
does indicate blockade of electron flow downstream of CoQ, which constitutes a 
favorable condition for AOX activation. The AOX-mediated mitigation of excess ROS 
production at cIII, and/or the prevention of metabolic stalling due to ETC inhibition, 
could be possible reasons for the ability of AOX to decrease the extent of cardiac 
dysfunction in young mice (12-16 weeks of age) overexpressing both Mcp1 and AOX. 
It should also be noted that the mitochondrial ETC is considered a key target of 
damage by excess ROS, as well as a possible source thereof. AOX should afford 
little or no protection against damage resulting from ROS produced elsewhere, e.g. 
due to NADPH oxidase, which is consistent with my observations. In a different study, 
preventing excess production of mitochondrial ROS, by introducing AOX was shown 
to exacerbate the phenotype of a mouse model with skeletal muscle-specific COX15 
knockout (Dogan et al., 2018). Unlike skeletal muscle cells, cardiomyocytes do not 
regenerate postnatally at a cellular level. Nevertheless, redox-sensitive signaling 
might be critical for initiating adaptive mechanisms in cardiomyocytes under 
conditions of chronic hypoxia (reviewed by Guzy and Schumacker, 2006; Santos et 
al., 2011). This might explain why AOX was unable to sustain the initial beneficial 
effects in older Mcp1 mice and, when expressed only in adult cardiomyocytes, 
actually led to a worsening of the phenotype. 
 
6.2.1. Pathology of Mcp1 mice 
Although Mcp1 expression has been shown to be beneficial in conditions of ischemic 
insult (Morimoto et al., 2006), its constitutive expression has proven detrimental in 
mice (Kolattukudi et al., 1998). This suggests a biphasic role of Mcp1, where its acute 
expression aids in tissue repair and prevents scar formation following an injury or 
infection, but prolonged expression eventually leads to tissue damage. MCP1 is a 
cytokine that is secreted by and can act directly or indirectly on several cell types, 
including immune cells and neighboring cells (reviewed by Deshmane et al., 2009, 
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Stow et al., 2009 and Conductier et al., 2010), thus having a complex role in tissue 
repair and remodeling. The overexpression of Mcp1 in adult cardiomyocytes is 
therefore expected to affect other cell types, including neighboring cardiomyocytes, 
endothelial cells, fibroblasts, resident immune cells and infiltrating monocytes. 
Although my study was not aimed at exploring the detailed effects of MCP1 on 
different cell-types, the differences are likely be critical for the progression of cardiac 
failure in Mcp1 mice. This is because of the inherent plasticity of resident cardiac 
cells. Apart from their specific roles in aiding cardiac function, they also undergo 
changes under conditions of tissue damage or injury to adapt and complement the 
loss of other cell types, especially cardiomyocytes (reviewed by Gray et al., 2018). In 
general terms, this could be one of the reasons behind the observed difference in the 
effects of global and cardiac-specific AOX expression in response to MCP1 insult. In 
mice expressing global AOX, all the cells, including endothelial cells, fibroblasts and 
immune cells, express AOX, which could have limited excess mitochondrial ROS 
production if the mitochondrial cytochrome pathway became damaged or overloaded, 
and thus provided protection against ROS damage within mitochondria. In contrast, 
in cardiac AOX mice, AOX expression is restricted to adult-cardiomyocytes. As a 
result, ROS damage occurring in other cell types would not be mitigated by AOX, 
whilst AOX activation in cardiomyocytes might result in decreased ATP production, 
exacerbating the pathological phenotype.  
 
6.2.2. Evidence for cardiac remodeling 
MCP1-induced adverse cardiac remodeling was confirmed by several observations, 
especially, by the switch in the expression levels of myosin heavy chain isoforms. An 
increase in the level of beta myosin heavy chain (Myh7) mRNA, which is expressed 
at a high level during fetal development, and a concomitant decrease in the mRNA 
for the adult-specific, alpha myosin heavy chain Myh6 (figure 20), indicates activation 
of the fetal-gene program, which has been observed previously in failing hearts 
(Allard et al., 1994; reviewed by Taegtmeyer et al., 2010). This was further supported 
by an increase in the expression level of GAPDH (figure 5C of paper (III)), compared 
to the controls, consistent with a shift towards increased glycolysis, a decrease in 
mitochondrial respiratory capacity (figure 19B), loss of cardiac contractile function 
(figure 18) and a clear shift in the global metabolome assessed by principal 
component analysis (figure 6 of paper (III)). Although the average lifespan of Mcp1 
mice was 35 weeks, all of these changes were already observable in early adulthood 
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(12 weeks of age). The molecular changes, plus the accompanying decrease in 
cardiac performance (figure 3 of paper (III)), are early signs of the pathological 
condition, and I hypothesize that the cumulative effect of metabolic disturbances and 
altered gene expression eventually results in cardiac failure. Global AOX expression 
in Mcp1 mice had only a small impact on these molecular parameters, indicating that 
mitochondrial involvement in the phenotype is not the result of any induced defect in 
mitochondrial metabolism, at least not one specifically affecting cIII and/or cIV, but is 
instead part of a global metabolic switch.  
 
6.2.3. Oxygen metabolism 
Subjecting Mcp1 mice to hyperoxic conditions, which was performed by my 
collaborators in Germany, mitigated cardiac contractile dysfunction and ultrastructural 
damage (figure 1 of paper (III)), suggesting that Mcp1-overexpression and/or the 
resulting infiltration of immune cells induces a hypoxic-like condition. In turn, this 
suggests the possibility that MCP1 acts by stabilizing HIF-1α, triggering HIF1-
mediated metabolic reprogramming, which includes the downregulation of 
mitochondrial respiration (Papandreou et al., 2006, Kim et al., 2006). This hypothesis 
is supported by the decreased respiration of isolated mitochondria from Mcp1 mouse 
heart (figure 19). Note, however, that, if this were limited by flux through cIII and cIV, 
AOX expression would be expected to restore it. However, respiratory limitation might 
be upstream of the cytochrome chain, involving an overall downregulation of the ETC 
and related metabolic pathways. This could be further tested by using an alternative 
NADH-ubiquinone oxidoreductase, e.g. Saccharomyces cerevisiae Ndi1. Like AOX, 
Ndi1 is a single subunit protein that is localized on the inner mitochondrial membrane 
and participates in the ETC without proton pumping, i.e. in other respects it functions 
similar to the mammalian cI by transferring electrons from NADH to ubiquinol (de 
Vries et al., 1988). In a recent study, preischemic administration of Ndi1 to 
Langendorff-perfused rat hearts decreased superoxide production, preserved ATP 
levels and mitochondrial integrity, and diminished the infarct size following ischemia-
reperfusion (I/R; Perry et al., 2011).  In addition, preischemic administration of Ndi1 
also decreased the infarct size in an in-vivo model for I/R injury (Mentzer et al., 2014).  
Given that Mcp1 overexpression does induce excess ROS production in 
cardiomyocytes (Niu et al., 2009), the counteracting effect of hyperoxic treatment on 
cardiac function would, taken in isolation, suggest a possible involvement of cIV in 
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the molecular mechanism, since cIV is the major oxygen-consuming enzyme of the 
cell. Although Mcp1 overexpression did not dramatically affect that of Cox1 (a subunit 
of cIV), it might have indirect effects on cIV activity. For example, Mcp1 mice exhibit 
elevated levels of iNOS (Niu et al., 2009), suggesting a possible regulation of cIV 
mediated by nitric oxide (Cleeter et al., 1994, Brown et al., 1994, reviewed by 
Erusalimsky et al., 2007). Another major site of ROS production is cI, where it is 
associated with reverse electron flow. Mcp1 overexpression also results in increased 
levels of TNFα and IL-1β (Niu et al., 2009), which could adversely affect the activity 
of cI and ATP production (Lopez-Armada et al., 2006, Mariappan et al., 2010). For 
example, in a study where TNFα was administered to rats, it resulted in LV 
dysfunction (Mariappan et al., 2010). The molecular changes involved decreased 
activity of the ETC complexes, especially cI, excess production of mitochondrial 
superoxide, and a decrease in ATP levels and MnSOD activity (Mariappan et al., 
2010). 
Taken together, Mcp1 overexpression may therefore have a broader effect on the 
mitochondrial ETC, thus negating any beneficial effects of AOX, which can only 
complement a blockade in the cytochrome pathway. 
 
6.2.4. Possible impact of AOX on macrophage polarization 
The polarization of monocytes into either pro-inflammatory (M1) or anti-inflammatory 
(M2) macrophages is regulated by the primary metabolic source of energy production 
within the cell, i.e. glycolysis or OXPHOS, respectively (reviewed by Galvan-Pena et 
al., 2014). Macrophages are activated by specific signals and vary in their functions. 
M1 macrophages are activated either by bacterial infections or administration of 
bacterial-derived products like lipopolysaccharides (LPS), whereas M2 macrophages 
are activated by parasitic infections and their related signals. Under conditions of 
tissue damage, an initial burst of M1 macrophages is followed by a switch to M2 type, 
to promote tissue repair, once the immediate danger has passed. The switch in the 
phenotype of macrophages has been suggested to be a consequence of alterations 
in ROS production, mitochondrial respiration and related metabolic pathways 
(reviewed by O’Neil et al., 2016). In support of this concept, AOX has been shown to 
mitigate LPS-induced lethality in mice, by limiting succinate accumulation and 
consequent ROS production resulting from reverse electron flow via cI (Mills et al., 
2016), which has been proposed to alter the expression levels of inflammatory genes. 
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Assuming a similar condition occurs in the MCP1-induced inflammatory response, 
global AOX expression should affect macrophage polarization in a similarly beneficial 
manner, whereas cardiomyocyte-specific AOX expression could not induce such a 
phenotypic change in macrophages. However, to clearly understand the impact of 
AOX expression in the polarization of macrophages, and determine the conditions 
that would influence an AOX-mediated phenotypic switch therein, a macrophage-
specific AOX expression model would be necessary.  
 
6.3. Lack of rescue of Cox10 KO mouse model by AOX 
Unlike previous observations where AOX prevented lethal effects of cIV dysfunction 
in human cell cultures and Drosophila models (Dassa et al., 2009, Fernandez-Ayala 
et al., 2009, Kemppainen et al., 2014), AOX was unable to rescue the lethal 
phenotype of cIV loss due to adult cardiomyocyte-specific COX10 KO in mice (figure 
21). As discussed above, active AOX is expected to complement defective cIII and/or 
cIV but at the cost of net ATP production. My observations indicate that restoring 
metabolic homeostasis may be more important than the overall level of mitochondrial 
ATP production in cultured cells or in smaller organisms such as fruit flies, but not in 
a mammalian organ like the heart which is heavily dependent on mitochondrial ATP 
production. Thus AOX was able to mitigate the severe phenotype resulting from 
knockdown of cIV or a cIV-biosynthetic gene in cells and flies, without causing severe 
adverse effects. However, this was not the case in the mouse, where proper cardiac 
function cannot be sustained if too great a decrease in ATP production occurs.  
There are several possible reasons to explain why adult cardiomyocyte-specific 
COX10 KO mice survived for up to two-weeks post-natally, but then succumbed. 
- Lactate produced via glycolysis is the major source of energy in 
cardiomyocytes during fetal development and is supplemented by fatty acid 
oxidation only after birth, when the cardiomyocytes are exposed to an oxygen-
rich environment (Bartelds et al., 2000). Thus during fetal development, loss 
of cIV should not have a major impact on cardiac development and function, 
despite having an active ETC. However, loss of cIV will adversely affect 
cardiac function once the switch to aerobic respiration occurs, and 
mitochondria become important as the main seat of ATP production. 
- COX10 KO is mediated by Cre-loxP activity, and KO in adult cardiomyocytes 
is achieved by driving Cre expression from an adult-cardiomyocyte specific 
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promoter, Myh6. In rodents, the expression of the adult-type (alpha) myosin 
heavy chain (Myh6) varies during fetal development, but is considered 
minimal from embryonic day 10.5 until birth. In contrast, the fetal (beta) 
isoform (Myh7) is maximally expressed throughout embryonic development 
but decreases to a minimal level after birth, when Myh6 attains maximum 
expression (Lyons et al., 1990). Therefore, the low activity of the Myh6 
promoter during development might not be sufficient to knockout both copies 
of COX10 in all cardiomyocytes until birth. 
- COX10 is an enzyme and its half-life may be long enough to sustain activity 
for an extended period of time subsequent to knockout of the gene. In such a 
case, loss of COX10 expression immediately after birth might not have a 
severe impact for many days, because of the presence of sufficient amounts 
of previously synthesized COX10 polypeptide (or its heme product). Ideally, 
this should be detectable by western blotting, but was not done in this study. 
This is supported by the observation from mice with heterozygous COX10 KO, 
which did not exhibit a deleterious phenotype, other than a mild decrease in 
cardiac contractile function. Additionally, the degradation of COX10 might 
happen only gradually, which could result in a gradual loss of cIV and thus not 





7. Conclusions and future prospects 
The work presented in this thesis explores the impact of mitochondrial respiratory 
defects in two mouse models of cardiomyopathy with different etiology. In the first 
model, Mcp1 overexpression in adult cardiomyocytes decreases mitochondrial 
respiratory capacity as a consequence of inflammation-mediated cellular stress, 
albeit by an unknown mechanism. In the second model, ETC dysfunction within the 
cytochrome pathway is induced in adult cardiomyocytes by excision of the gene for 
COX10, an enzyme essential for biogenesis of the prosthetic group in cIV. These 
mouse models can be considered complementary, since mitochondrial impairment in 
the two cases is the respective consequence of indirect and direct insults, providing 
a broad perspective on ETC dysfunction. By expressing AOX in these disease 
models, I was able to further understand the importance of ATP production and redox 
balance in the pathogenesis of cardiomyopathy. In addition, this study implicitly 
investigated the therapeutic potential of AOX for diseases involving mitochondrial 
respiratory defects. 
AOX has been lost during the course of evolution in mammals. Nevertheless, it has 
biochemical properties and biological functions that protect its natural hosts from 
stress conditions that closely replicate human disease. This raised the question of 
whether a therapeutic use of AOX could be beneficial, provided it does not evoke 
detrimental side effects that counteract putatively beneficial consequences. A better 
understanding of the bioenergetic consequences of xenotopic AOX expression e.g. 
on regular physiology and stress-response mechanisms was thus a prerequisite for 
its use. This was tested using a model organism approach by xenotopic expression 
in the mouse. Recently several model organisms with transgenic AOX expression 
were generated, and were exposed to different stresses affecting mitochondrial 
function. AoxRosa26 mice, described in (I), constitute one such model. In my first study 
(I), I characterized the AoxRosa26 mouse model under non-stressed and moderately 
stressed conditions. From my observations, I conclude that Ciona AOX can be safely 
expressed in mice and does not alter normal physiology under non-stress conditions. 
Yet, it provides resistance to a lethal dose of cyanide, i.e. a potent inhibitor of cIV of 
the ETC. I have reasoned that the lack of change in the physiology of AoxRosa26 mice, 
when compared to wild-type mice, is due to the enzymatic inactivity of AOX under 
standard physiological conditions. This is crucial information, considering the 
potential therapeutic use of AOX, supporting the proposition that it may be 
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administered safely. However, as discussed above, a more thorough longitudinal 
analysis of all relevant parameters, would be essential for testing the long-term effects 
of AOX administration.  
In my second study (II), I have addressed the issue raised above, by exposing 
AoxRosa26 mice to dietary stress for a 40 week period. Against my expectation, I 
conclude that AOX expression has only minor effects on the phenotype induced by 
chronic exposure to fat-rich diets. The lack of a severe effect of AOX in mice exposed 
to fat-rich diets provides further evidence for its enzymatic inactivity under conditions 
that may not directly affect the ETC. Despite evidence from elsewhere that fat-rich 
diets may compromise mitochondrial function, I found no consistent evidence for a 
significant negative interaction between AOX expression and nutritional stress of this 
type. Alternatively, since AOX affected the lean mass in mice in a diet-independent 
manner, although not significantly different from the wild-type mice, it argues for a 
possible impact of AOX on overall catabolism in mice. This could be further 
investigated using a different experimental set up, where AOX mice are subjected to 
a calorically restricted diet.  These mice would then be tested to see if an altered 
energy metabolism is induced, thereby severely affecting the muscle mass and/or the 
activity of the mice. 
Validation of the AoxRosa26 mouse model in studies (I) and (II) laid the foundation for 
its combination with the above-mentioned cardiomyopathy models. From my third 
study (III), I conclude the following; 
(i) AOX expression can be restricted to adult-cardiomyocytes, and does not 
induce any adverse phenotype on its own. 
(ii) In conditions of inflammatory cardiomyopathy, AOX expression is able to 
provide only a transiently beneficial effect in young mice. 
(iii) Cardiomyocyte-specific AOX expression exacerbates the harmful cardiac 
phenotype of Mcp1 overexpression. 
(iv) AOX expression does not prevent the lethal phenotype of COX10 KO in 
adult cardiomyocytes in mice. 
In this study, AOX did not confer protection against the detrimental effects of 
excessive inflammation in the heart but, in a different study, it was protective against 
a LPS-induced lethal phenotype (Mills et al., 2016). Although the cause of lethality 
under both conditions is assumed to be excessive inflammation, the induced 
metabolic conditions affected the impact of AOX differently. Additionally, the adverse 
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effect of cardiomyocyte-specific AOX expression on Mcp1 overexpression mice 
raises the possible role of AOX in macrophage maturation. The impact of AOX on the 
maturation of infiltrating macrophages can be tested by utilizing bone-marrow 
transplantation technique. Briefly, the bone marrow of the Mcp1 mice (host) can be 
depleted by irradiation, followed by engrafting bone marrow cells from AoxRosa26 mice 
(donor). The resulting chimeric mice will have MCP1 over-expression in the adult 
cardiomyocytes and AOX expression in the bone marrow-derived cells, and studying 
the specific effect of AOX on macrophage polarization and thereby its impact on the 
Mcp1-induced phenotype would also be informative. A potential challenge in this 
system would be the time of irradiation. The typical age for irradiating mice is above 
10 weeks after birth and a complete replenishment of the bone marrow derived cells 
would take about 10 weeks post transplantation. Since the Mcp1 mice develop a 
cardiac phenotype at an early age, detectable at 12 weeks of age, the bone-marrow 
transplantation might not be effective in preventing the development of the cardiac 
phenotype. However, this experiment could still provide valuable insights on the 
impact of macrophage polarization in the progression of cardiac contractile failure, 
provided that AOX can indeed be demonstrated to affect macrophage maturation. For 
a comprehensive review on bone-marrow transplantation technique and its limitations 
with respect to studies on cardiovascular diseases, see Aparicio-Vergara et al., 
(2010). Alternatively, AOX expressed under a macrophage-specific Cre driver will 
also be resourceful to study the effect of AOX expression in macrophage maturation. 
We are just starting to understand the impact of AOX expression in mammals and 
several recent studies have shown differential beneficial effects of AOX in respective 
disease conditions. In order to better understand the potential of AOX as a therapeutic 
option, further studies are required to elucidate the regulatory and stress response 
mechanisms in different organs that may be affected by the catalytic AOX 
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